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ABSTRACT 
 
Systems biology explores how the components that constitute a biological system interact with 
each other to produce biological phenotypes. A number of tools for comprehensive and high-
throughput measurements of DNA/RNA, protein and metabolites have been developed. Each of 
these technologies helps to characterize individual components of the genome, proteome or 
metabolome and offers a distinct perspective about the system structure. My dissertation aims to 
characterize and analyze multiple types of omics data using existing and novel network-based 
approaches to better understand disease development mechanisms and improve disease diagnosis 
and prognosis.  
The transcriptome reflects the expression level of mRNAs in single cells or a population of cells. 
Understanding the transcriptome is an essential part of understanding organism development and 
disease. The first part of my thesis work focused on analyzing transcriptome data to characterize 
aggressiveness and heterogeneity of human astrocytoma, the most common glioma with a 
strikingly high mortality rate. A large-scale global gene expression analysis was performed to 
analyze gene expression profiles representing hundreds of samples generated by oligonucleotide 
microarrays. I employed a combination of gene- and network-based approaches to investigate the 
genetic and biological mechanisms implicated in observed phenotypic differences. I observed 
increasing dysregulation with increasing tumor grade and concluded that transcriptomic 
heterogeneity, observed at the population scale, is generally correlated with increasingly 
aggressive phenotypes. Heterogeneity in high-grade astrocytomas also manifests as differences 
in clinical outcomes and significant efforts had been devoted to identify subtypes within high-
grade astrocytomas that have large differences in prognosis. I developed an automated network 
screening approach which could identify networks capable of predicting subtypes with 
differential survival in high-grade astrocytomas.  
The proteome represents the translated product of the mRNA, and proteomics measurement 
provides a direct estimate of protein abundance. For the second part of my Ph.D. research, I 
analyzed mouse brain protein measurements collected by the iTRAQ technology to query and 
identify dynamically perturbed modules in progressive mouse models of glioblastoma. Network 
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behavior changes in early, middle and late stages of tumor development in genetically 
engineered mouse were tracked and 19 genes were selected for further confirmation of their roles 
in glioblastoma progression. In addition to this specific application to mouse glioblastoma data, 
the general pipeline represented a novel effort to isolate pathway-level responses to perturbations 
(e.g., brain tumor formation and progression) from large-scale proteomics data and could be 
applied in analyzing proteomics data from a variety of different contexts. 
The metabolome reflects biological information related to biochemical processes and metabolic 
networks involving metabolites. Metabolomics data can give an instantaneous snapshot of the 
current state of the cell and thus offers a distinct view of the effects of diet, drugs and disease on 
the model organism. The third part of my thesis is dedicated to building and refining genome-
scale in silico metabolic models for mouse, in order to investigate how the metabolic model 
responds differently under different conditions (e.g., diabetic vs. normal). This project was 
completed in two stages: first, I examined the state-of-art genome-scale mouse metabolic model, 
identified its limitations, and then improved and refined its functionality; second, I created the 
first liver-specific metabolic models from the generic mouse models by pruning reactions that 
lack genetic evidence of presence, and then adding liver-specific reactions that represent the 
characteristics and functions of the mouse liver. Finally, I reconstructed two liver metabolic 
models for mouse, with one for the normal (control) strain and one for mouse diabetic strains. 
These two models were compared physiologically to infer metabolic genes that were most 
impacted by the onset of diabetes. 
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CHAPTER 1: INTRODUCTION AND OVERVIEW 
 
1.1 A SYSTEMS APPROACH TO EXPLORING LIVING ORGANISMS 
 
More than a decade has passed since the term systems biology has been introduced into the 
language of modern biology [1]. Over the years, its definition has expanded greatly in its 
width and depth, but one central aspect of systems biology remains unique: it studies how the 
components that constitute the biological system interact with each other. Disease is 
becoming more generally perceived as the result of one or more genetically or 
environmentally perturbed biological networks [2]. As such, to better understand genotype-
to-phenotype relationships, we must focus our attention more on the interaction and 
dynamics of biological systems instead of only looking at the individual components of 
biological processes. This systems approach is in contrast to the classical reductionist 
approach, where biological systems are dissected into their constituent components. This 
traditional approach was once successful in the early days of biology, but it has reached its 
limits after more and more biologists realized the complexities of living systems cannot be 
explained fully by studying and viewing the components as disparate or disconnected. The 
system-level perspective offers an alternative to explain how individual pieces create the 
whole, or how genes interact to create a system-wide phenotype and behavior [3]. The 
different emphases of the two views are illustrated in Figure 1.1.  
 
In order to learn and understand how fundamental biological processes interact with each 
other, we need to connect two types of information together: the DNA sequence of the 
genome and the environmental signals and information that operate through living organisms 
to generate phenotypic responses [4]. To follow the dynamic networks and learn their 
responses to perturbations, a number of tools aiming for comprehensive and high-throughput 
measurements of DNA/RNA, protein and metabolites have been developed.  Each of them 
helps to characterize individual components of the genome, proteome or metabolome and 
offers a different slice of information about the model organism. In the next section, I will 
give a brief overview of the different high-throughput technologies to address specific 
hypothesis-driven questions.  
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1.2 OMICS DATA TO PROFILE AND CHARACTERIZE DISEASE 
 
The first type of omics data is transcriptomics. The transcriptome is a collective term for 
different RNA molecules, including messenger RNA (mRNA), which carries genetic 
information transcribed from DNA; ribosomal RNA (rRNA), the RNA component of the 
ribosome that is essential for protein synthesis; transfer RNA (tRNA) which physically 
connects nucleic acids and amino acids, as well as non-coding RNAs (RNAs that are not 
translated into proteins). The study of transcriptomics, also known as expression profiling, 
quantifies the expression level of mRNAs in a given cell population [5]. Understanding the 
transcriptome is essential to understanding development and disease: by measuring the 
differentially expressed transcripts under different conditions (e.g. disease vs. control), we 
could infer the functional elements of the genome and reveal key players in disease initiation 
and development. Different high-throughput technologies have been developed to measure 
the transcriptome, including the hybridization-based microarray as well as the newer, 
emerging sequence-based technology called RNA-seq. The core biological principle behind 
microarray is the hybridization between two complementary DNA strands, which pair up 
with each other by forming hydrogen bonds (Figure 1.2a). In contrast to microarray 
methods, RNA sequencing technologies directly measure the cDNA sequence and are able to 
provide a more concise estimate of the gene expression value [5]. However, sample 
collection using microarray hybridization is more affordable, more accessible and many 
more samples are available in data repositories, compared to data collected by RNA 
sequencing. A significant portion of my thesis was devoted to studying microarray data of 
brain cancer patients: collecting, normalizing, and comparing gene expression levels under 
different conditions, and developing data processing pipelines to better characterize brain 
cancer initialization and progression. 
 
The transcriptome can be seen as a precursor for the proteome, which represents the 
translated product of the mRNA. However, mRNA is not always translated into protein [6] 
and mRNA level is not the sole factor determining translated protein content. What further 
complicates the picture is the fact that proteins may undergo a wide variety of chemical 
modifications after translation, collectively known as post-translational modification. 
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Alternative splicing of the transcripts, where a single gene or transcript encode for multiple 
proteins [7] also explain why mRNA is often found not to be correlated highly with protein 
content [8]. Proteomics confirms the presence of protein, provides a direct measure of the 
amount of protein present, and gives a better understanding of the state of the living 
organism than genomics [9]. 
Mass spectrometry (mass spec) is an important technology to characterize protein content. It 
can be used as a valuable tool to identify and probe the covalent structure of proteins [10]. 
Another use of mass spec in proteomics is protein quantification. iTRAQ is a non-gel-based 
technique developed to quantify proteins by analyzing the derivatization of primary amino 
groups in proteins using isobaric tags [11]. Specifically, iTRAQ facilitates the comparative 
analysis of peptides and proteins in different conditions. The proteomics study in my Ph.D. 
research analyzed mouse brain protein measurements collected by the iTRAQ method and 
developed a general pipeline to isolate pathway-level responses to perturbations (e.g. brain 
tumor formation and progression) from large-scale proteomics data. 
In addition to transcriptomics and proteomics, metabolomics is a systems biology view on 
the interactions of metabolic pathways within an organics, which offers us fresh insights into 
the effects of diet, drugs, and disease. The metabolome reflects biological information exists 
in biochemical processes involving metabolites, which are the intermediates and end 
products of metabolism [12]. While transcriptomic and proteomic analyses do not tell the 
complete story of the underlying processes in a cell, metabolomics study can give an 
instantaneous snapshot of the current state of the cell.  
After the omics data have been generated, the next step is to identify all the components of a 
system, establishing their interactions and assessing their dynamics [13]. An effective way 
to integrate and interrogate these disparate types of information is using in silico models. In 
silico or computational modeling lies at the core of systems biology and it has evolved to be 
a valuable, fast and accurate tool to predict responses to various hypotheses. With increasing 
omics and clinical data, researchers have built complete and more realistic models that are 
beginning to produce lab-proven results.  These dry lab models help to frame more focused 
questions and design better laboratory experiments and clinical trial protocols.  One type of 
computational model is a genome-scale metabolic model. A metabolic model is a 
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mathematical representation of the biochemical transformations in the metabolic network of 
an organism. A network consists of multiple reactions happening in order, and a reaction 
consists of reactants and products (metabolites) as well as the genes catalyzing the reaction 
(Figure 1.3). If whole genome sequences are integrated with metabolic biochemical 
networks, a genome-scale metabolic model is constructed. The third part of my thesis is 
dedicated to building and refining genome-scale in silico metabolic models for mouse in 
order to study how the metabolic model respond differently under different conditions (e.g. 
diabetic vs. normal). 
1.3 DISSERTATION ORGANIZATION 
 
The goals of the work presented in my dissertation were to 1) investigate and explore cancer 
aggressiveness and heterogeneity in the context of human astrocytoma, using transcriptomic 
data 2) develop a framework to learn and quantify network-level changes in response to 
tumor progression in the context of mouse glioblastoma, using proteomics data 3) develop 
and refine genome-wide metabolic models for mouse liver,  under normal and diabetic 
conditions, using the mouse genome-scale metabolic network reconstruction as a starting 
point.  
 
In virtually all of my research projects, I was fortunate enough to interact and collaborate 
with many biologists, computer scientists and bioinformatics scientists. Without the 
numerous inspiring discussions and intellectual exchanges of information, none of the 
projects could have reached this far. In subsequent chapters of this dissertation, I have used 
the singular “I” to clarify ideas and analysis that I was directly responsible and “we” to 
indicate a more collaborative effort.  
 
The chapters in this dissertation are organized as follows: 
Chapter 1: Introduces the concept of systems biology and how transcriptomic, proteomic 
and metabolomic data each offer a distinct systems perspective to study the living organism. 
Chapter 2: Describes and summarizes the major observations and key results in the study of 
human astrocytoma using large-scale gene expression profiles. 
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Chapter 3: Presents the discovery of a novel prognostic network that could possibly 
distinguish different subtypes within aggressive human gliomas. 
Chapter 4: Describes a computational framework to discover key players in genetically 
engineered mice with induced mutations to drive glioma progression.  
Chapter 5: Examines the generic mouse model and suggests key functionality 
improvements that will provide a foundation on which to build metabolic models for mouse 
liver. Subsequently, I present the pipeline to reconstruct a liver model from the generic 
mouse model, and explain the construction processes of two versions: normal and diabetic 
liver models. 
Chapter 6: Provides a summary and conclusions for the work presented, and list future 
directions of my work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
1.4 CHAPTER 1 FIGURES 
 
 
Figure 1.1 The two views on biological systems: the reductionist view knows the precise states of 
all the organs and cells in the body; the systems view takes account of interactions among all 
components, and offers us a global perspective on the system as a whole. Adapted from [14] . 
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Figure 1.2 A) Hybridization step in microarray B) Heapmap of gene expression values 
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Figure 1.3 Structure of genome-scale metabolic network. Adapted from Systems Biology lecture 
slides, B.Ø. Palsson, UCSD 
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CHAPTER 2 UTILIZING TRANSCRIPTOMIC PROFILING TO EXPLORE 
AGGRESSIVENESS AND HETEROGENEITY OF BRAIN CANCER
1 
 
2.1 INTRODUCTION TO HUMAN ASTROCYTOMA 
 
Primary brain tumors comprise less than 2% of all human cancers but have strikingly high 
mortality rates. Glioma, the most prevalent primary brain tumor, accounts for ~42% of all 
adult brain tumors [15]. The most common gliomas, in turn, are astrocytomas, believed to 
originate from astrocytes [16, 17]. Astrocytomas are classified from grade 1 (least 
aggressive) to grade 4 (most aggressive) based on the World Health Organization (WHO) 
grading system [18].  
 
Presented here is my work on the analysis of the different grades of astrocytoma (excluding 
pilocytic astrocytoma, with normal brain tissues taken as control) to identify both distinct 
and common molecular states across grades. I have employed a combination of gene- and 
network-based approaches (Figure 2.1) to investigate the genetic and biological 
mechanisms implicated in observed phenotypic differences.  
 
Grade 1 tumors (pilocytic astrocytomas) represent distinct pathological and biological 
entities compared with other tumors [19] and thus were not included in this study. As such, I 
henceforth considered only grades 2 through 4. Grade 2 (G2) and grade 3 (G3) tend to 
progress to higher grades with recurrence. Grade 4 tumors (glioblastoma multiforme or 
GBM) commonly present as primary tumors (pGBM), with no prior history of occurrence at 
a lower grade. Secondary GBM (sGBM), on the other hand, has recurred in a patient 
previously diagnosed and treated for a lower grade [20]. Specific avenues of progression 
where astrocytoma manifests in G2 tumors that undergo transformation to the more 
aggressive G3 or GBM tumors, have been seen in both genetically engineered mouse 
models [21], as well as in humans [20]. My study included only GBMs with clear subtype 
                                                     
1 This chapter includes material that was reproduced with permission from the following publication: C Wang, CC 
Funk, JA Eddy, ND Price (2013) Transcriptional Analysis of Aggressiveness and Heterogeneity across Grades of 
Astrocytomas. PLoS ONE 8(10): e76694. doi:10.1371/journal.pone.0076694 (all sections; text was collaboratively 
written with Cory Funk, James Eddy and Nathan Price). 
10 
 
designations (primary or secondary) and investigates differences between GBMs and lower 
grades as well as between these subtypes. 
 
2.2 GENE EXPRESSION PROFILING: CHALLENGES AND STRATEGIES 
 
A lot of transcriptomic studies have been done on human astrocytoma and differentially 
expressed genes and molecular signatures have been identified in previous microarray 
experiments, in an attempt to address clinical needs [22-27]. Unfortunately, as most of these 
studies were statistically underpowered, these signatures failed on independent validation 
sets, thus rendering them ineffectual [28]. Lab effect can obfuscate signal from noise in 
phenotypically similar tumors if sampled from different studies [29]. This can be overcome 
through use of multiple data sets when properly normalized—also minimizing the inherent 
biological noise [30]. Our present study adopted such a uniform approach to process raw 
expression data from multiple labs with one standard adjustment method, thereby increasing 
sample-to-sample correlation and decreasing heterogeneity across the data collected in 
different studies (Figure 2.1A). 
 
Another strategy to mitigate biological noise is to analyze molecular profiles from 
individual genes or proteins in the context of biological network behaviors, and helps to link 
changes in gene expression to phenotype. Studying network behavior is especially relevant 
in cancer research as cancer stages and progression are marked by changes in network-level 
processes [31]. My research lab had previously developed a method called Differential Rank 
Conservation (DIRAC) [32], which measures the variation in network ranking (i.e., the 
relative ordering of genes from highest to lowest expression within a pre-defined network) 
among samples of the same phenotype and between samples of different phenotypes 
(Figure 2.1C). This enables evaluation of changes in gene expression at a network level 
based on relative expression between each of the network components, making the method 
independent of any normalization that does not affect rank (e.g., normalizing to total RNA, 
quantile normalization, etc.); additionally, the results do not depend on the other genes in the 
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transcriptome, meaning that it can be applied when only the genes in the network are 
measured.  
 
After explaining the key challenges in transcriptomic study and my strategies to address the 
problem, I will present the major observations and improvements in the next section. 
2.3 CONSENSUS PRE-PROCESSING REDUCES NOISE 
 
Appropriate computational pre-processing is an important step in combined analyses of 
multi-site data to reduce technical variability between different studies. Consensus pre-
processing, which normalizes raw expression data from multiple studies in a uniform 
manner, has been shown to reduce lab effects known to obfuscate biological signal when 
combining datasets from multiple labs [30]. Molecular signatures obtained after this step of 
processing have better prediction accuracy and lower variance than those from individual 
datasets. For example, average accuracy obtained training on four GBM datasets was 
considerably higher than training on individual GBM datasets [30]. We applied consensus 
pre-processing to the raw expression data for 336 patients collected from multiple 
independent studies. This greatly reduced sources of variation across studies, as measured 
by an increase in average sample-to-sample correlation from 81% to 91% (Figure 2.2). 
Reducing noise in the data enabled a more robust identification of variability across 
phenotypes. 
2.4 GLOBAL DYSREGULATION OF NETWORKS 
 
We first investigated global differences in network-level expression between astrocytoma 
grades by applying DIRAC to measure the rank conservation index of relative stability or 
consistency within each network ordering across a population [32]. If the orderings of genes 
within a specific network are mostly similar among different patients (i.e., highly conserved), 
the network is considered consistent within a phenotype. In the opposite case, more 
dissimilarity among patients is observed, and the network is considered heterogeneous or 
dysregulated. Extending this concept, averaging rank conservation indices over all networks 
provides a coarse measure of global regulation in different phenotypes.  
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We found that networks in normal brains are on average more highly conserved (0.957) than 
networks in advanced astrocytoma grades (G2, 0.937; G3, 0.930; and GBM (including both 
pGBM and sGBM), 0.915; P < 0.001 for ordering of phenotypes, based on one-way 
ANOVA) (Figure 2.3A&2.3B). In addition, global network rank conservation is 
significantly different between all pairs of phenotypes (P < 0.05, multiple pairwise t-tests). 
This trend demonstrates that more aggressive phenotypes have greater overall variation in 
network ordering among different samples. Increased genetic and cellular heterogeneity is a 
commonly recognized characteristic of highly malignant astrocytomas [33, 34]. GBM, the 
most malignant grade, is characterized by extensive heterogeneity as reflected in the 
moniker “multiforme,” which derives from early histopathologic descriptions of a single 
tumor's highly varied morphologic features and connotes cellular heterogeneity [35]. Here, 
we show in a quantitative manner that transcriptomic heterogeneity, observed at the 
population scale, is generally correlated with increasingly aggressive phenotypes. 
2.5 DIFFERENTIALLY REGULATED NETWORKS BETWEEN DISEASE STATES  
 
Certain networks appear consistent in one phenotype but show drastically more sample-to-
sample heterogeneity in another phenotype. Identifying the most differentially regulated 
networks can inform us about cellular processes and mechanisms most affected or perturbed 
from one disease state to another. We thus identified the most differentially regulated 
networks between normal samples and different astrocytoma grades as well as between 
different disease states (Table 2.1). For example, we identified 12 out of 248 networks that 
had a significant difference in conservation in comparing normal to G2 patients (P < 0.01 
for each comparison, based on a binomial distribution; see Chapter 2.9 Methods); 10 out of 
these 12 networks showed increased dysregulation in G2. Similarly, in comparing G2 to G3, 
G3 to primary or secondary GBM, a strong majority of significantly dysregulated networks 
exhibited greater heterogeneity in the more malignant phenotype (Figure 2.3) (P < 0.01 for 
each comparison, based on a binomial distribution). These quantitative results further 
support the idea that networks become increasingly dysregulated with increased malignancy.  
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2.5.1 DYSREGULATED NETWORKS IN G2 VS. NORMAL 
 
Among the 12 significantly differentially regulated networks (P < 0.01) between G2 and 
normal brain, 5 networks (PLCD, PLCE, AKAP13, CCR5, and ION) are known to 
regulate protein kinase C (PKC) signaling and increase calcium release into the cell (Figure 
2.3). Calcium signaling is a key player in neuronal transmission, microglia activation, and 
motility. Calcium signaling is especially crucial for transformed glioma cells to expand in 
the early stages of tumor development by sheer motility, as glioma cells cannot spread 
through the bloodstream [36]. Similarly, hyperactive PKC signaling is among the most 
distinguishing features of malignant brain tumors. PKC signaling stimulates both 
MAPK/ERK and PI3K/AKT pathways; it also supports degradation of extracellular matrices 
and allows for invasion of glioma cells [31].  
 
Three networks, ACETAMINOPHEN, SLRP, and PEPI, mediating immune system 
responses, also showed increased dysregulation in G2 patients (Figure 2.3C). The 
ACETAMINOPHEN network was named after the commonly used drug Acetaminophen 
to reduce pain, targeting the cyclooxygenase enzymes. This network is also involved in 
inducing expansion of myeloid-derived suppressor cells (MDSC), which suppress T-cell 
responses to tumor growth [37]. Increased instability of this network may contribute to 
gliomagenesis by supporting development of MDSCs and their accumulation in the tumor 
microenvironment [38]. The SLRP network consists of 5 small leucine-rich proteoglycans 
(SLRPs), which are ligands of the Toll-like receptors responsible of regulating innate 
inflammatory response [39].  
 
In contrast to the ACETAMINOPHEN and SLRP networks, PEPI showed significantly 
more consistent expression ordering in the cancer population (0.877 in normal and 0.945 in 
G2 patients, P = 0.006). This network activates neutrophils and generates the wound 
cleaning response—and is likely indicative of the normal physiological response to most 
tumors. In the early stage of forming malignant glioma cells, it is possible that some 
immune-related networks like PEPI act to prevent tumor cell migration and invasion 
through a more consistent expression program, while the dysregulation of other networks 
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like SLRP and ACETAMINOPHEN contributes to the immunosuppressive environment in 
the tumor.  
2.5.2 DYSREGULATED NETWORKS IN G3 VS. G2  
 
Comparing network states in high-grade G3 to low-grade G2, all 5 networks with significant 
change in consistency of gene ordering showed greater heterogeneity in the more aggressive 
cancer grade (Figure 2.3C). ERBB4 and NOTCH networks are part of the larger 
EGFR/ErbB signaling pathway. The key components in this pathway consist of four 
members of ErbB family of proteins (Erb1-4), which tend to form heterodimers and bind 
several cognate growth factors (e.g. EGF, TGF), activating downstream transcription factors 
(e.g. JUN, FOS) to regulate multiple cellular responses including proliferation and apoptosis 
[40]. This pathway has demonstrated substantial biological and transcriptional consequences 
such as activating downstream PI3K/AKT, PKC, and MAPK/ERK pathways. Up to 40% of 
GBMs display deletions in EGFR rendering it constitutively active, while others 
overexpress it through amplification or up-regulation of expression [41].  
 
The NOTCH network interacts closely with EGFR to facilitate tumor angiogenesis. Our 
observation that NOTCH shows greater variability in expression ordering at the higher 
grade—from 0.908 (in G2 tumors) to 0.856 (in G3 tumors)—supports the hypothesis that it 
plays different roles in tumorigenesis of low-grade astrocytomas and high grade gliomas. 
That is, while inactive NOTCH functions as a tumor suppressor in low-grade G2 tumors, it 
is activated and may act as an oncogene in high grade astrocytomas, especially primary 
GBM [42]. 
 
The TERT network, responsible for telomerase activation, also showed greater 
dysregulation in G3 compared to G2. Telomerase activation and subsequent telomere 
maintenance are generally associated with the malignant transformation of normal cells to 
cancer cells [43]. The increased transcriptomic heterogeneity and network ordering 
inconsistency in higher grade astrocytomas further supports the known fact of telomerase 
dysregulation in malignant cancer phenotypes [44].  
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2.5.3 DYSREGULATED NETWORKS IN GBM VS. G3  
 
We compared network conservation values between G3 and primary GBM and between G3 
and secondary GBM separately, and obtained 38 and 16 differentially regulated networks, 
respectively. 13 networks appeared as significant in both comparisons (P < 0.01). GBM 
displays all the pathological features in the lower grades such as altered regulation in 
transcription and metabolism, calcium, and EGFR signaling (Figure 2.3C). 
 
The PLCD, PLC, TRKA, and HBX networks all regulate release of intracellular calcium 
and function in similar ways as PLCE and PKC, identified in the lower grades. Notably, 
HBX includes 4 genes (GRB2, HRAS, SHC1, SOS1) that are part of the PI3K/AKT 
pathway—known  to be hyperactivated in GBMs, resulting in uncontrolled cell growth, 
survival, proliferation, angiogenesis, and migration [45].  
 
As expected, there are a number of networks involved in the complex EGFR regulatory 
pathway as in the other grades. The CBL network contains the ubiquitin ligase Cbl which 
degrades EGFR, thus down-regulates EGFR signaling [40, 46]; the ERBB3 network 
likewise contains functionally similar components and plays a similar role in EGFR 
signaling. TERC, another network in this list, behaves like TERT to control telomerase 
regulation.  
 
Interestingly, two networks (LDL and S1P) with critical roles in cholesterol metabolism 
also displayed significant dysregulation in GBM. LDL transports cholesterol, which is 
needed for cell membrane repair and synthesis, whereas S1P controls transcriptional 
regulation of cholesterol metabolism in response to cholesterol levels in the cell [47]. In 
addition, S1P connects to the earlier mentioned EGFR pathway through two sterol-
regulatory element-binding proteins (SREBF1 and SREBF2) that are activated by PI3K. The 
interplay between S1P, SREB proteins and EGFR regulate the expression of fatty-acid 
synthase, which synthesize fatty acid and plays key role in cancer pathogenesis [48]. It has 
been reported the EGFR mutations (EGFRVIII) and PI3K promote tumor growth and 
survival through SREBP-1 dependent lipogenesis [49].  
16 
 
2.5.4 DYSREGULATED NETWORK DISTINGUISHING PGBM FROM SGBM  
 
In comparing the two subtypes of GBM, primary to secondary GBM, it is interesting to note 
that the conservation value of S1P also decreased significantly from 0.812 in primary GBM 
to 0.769 in secondary GBM (P = 0.005). The SREBF1 gene in this network regulates and 
activates the IDH1 gene [50]. IDH mutations are commonly observed in lower grade and 
secondary GBMs but rarely in primary GBMs [51]. Thus, this network links IDH mutation 
to lipid homeostasis. Increased network dysregulation of S1P in secondary GBM offers 
quantitative support that IDH signaling is altered in this subset of GBMs. 
2.6 MONOTONICALLY INCREASING AND DECREASING GENES IN ASTROCYTOMA 
PROGRESSION 
 
Amidst the increased dysregulation of gene networks with increasing astrocytoma grade, we 
sought to identify instances where specific molecular changes—in this case, changes in 
expression of individual genes—occur in a unidirectional manner. We reasoned that such 
instances could provide insight into the oncogenic mechanisms or events that contribute to 
the pathology and/or transcriptomic heterogeneity found in astrocytoma. We therefore 
looked for genes whose expression level monotonically changed concomitant with 
increasing grade.  
 
31 and 6 genes were found to decrease or increase their respective expression from normal 
to G2, G3, and GBM (Figure 2.4, Table 2.2). In evaluating DEGs between G3 and GBM, 
only genes differentially expressed in both pGBM and sGBM compared to G3 were 
included (see Chapter 2.9 Methods). We also tested for the statistical significance of the 
directionality of the genes (P < 0.001, see Chapter 2.9 Methods). The fact that specific 
genes change consistently with increasing astrocytoma grade may reflect shared oncogenic 
mechanisms among phenotypically similar tumors. Interestingly, similar to the differentially 
regulated networks, several of these genes identified are also associated with key processes 
such as calcium signaling and metabolism and/or are located in the endoplasmic reticulum 
(ER) or mitochondria. The commonalities shared by gene-based and network-based analysis 
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may represent potential connections between genetic heterogeneity at the tumor level and 
expression heterogeneity at the population level.  
 
The significance of calcium signaling and metabolic genes may relate to how cells respond 
to additional metabolic requirements needed for tumor cell division and cell cycle 
progression with increased aggressiveness. At the same time, cells that ultimately constitute 
the tumor mass have been selected for their ability to avoid apoptosis while facilitating the 
increased metabolic flux. As such, we see genes implicated in regulation of apoptosis. We 
discuss in detail below how representative genes are involved in the above-mentioned 
functional categories and how they interact to bring about changes reflective of astrocytoma 
pathology. A summary of the genes and their respective functions is shown in Figure 2.5.  
2.6.1 GENES IMPLICATED IN CALCIUM SIGNALING AND/OR APOPTOSIS 
 
Among the monotonically changing genes, TMEM66, STRN3, CANX, and CPEB3 are 
known to affect calcium and apoptotic signaling; all of them, with the exception of CANX, 
showed decreased expression with increasing tumor grade.  
 
TMEM66, also known as SARAF, is localized to the ER lumen and affects calcium storage 
[52]. Following calcium release from the ER, calcium stores are replenished through 
calcium release activated channels (CRAC) to re-enter the ER lumen [53]. Decreased 
SARAF, as we observed in our study, would potentially lead to an inability to close the 
CRAC channels and disrupt calcium homeostasis in aggressive gliomas.  
 
Striatin, calmodulin binding protein 3 (STRN3) is another monotonically decreasing gene 
and participates in apoptosis and calcium release. It is found to be both cytosolic and 
membrane-bound and is expressed primarily in the brain and muscle [54]. STRN3 binds 
with calmodulin in the presence of calcium [55]. It reacts with protein phosphatase 2a 
(PP2a), which, along with the promyelocytic leukemia (PML) protein, stimulates IP3R-
mediated Ca2+ release from ER. PML modulates calcium-mediated apoptotic stimuli 
through binding with PP2a and IP3R [56]. Decreased expression of STRN3 in aggressive 
gliomas likely reflects changed apoptotic calcium signaling mechanisms in these tumors. 
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Cytoplasmic polyadenylation element binding protein 3 (CPEB3) is a nucleocytoplasmic 
shuttling RNA-binding protein. It is involved in both calcium signaling and EGFR 
degradation. CPEB3 inhibits EGFR expression by preventing the translation of STAT5B, a 
regulator of EGFR transcription [57]. As a monotonically decreasing gene, lower expression 
of CPEB3 would similarly lead to an increase in EGFR. Notably, CPEB3 is located on 
chr10q 23.32, very close to the locus of PTEN (chr10q 23.31). Loss of this region is known 
to occur in several cancers [58] and it is conceivable that loss of CPEB3 contributes to 
altered EGFR signaling along with PTEN loss. 
 
In contrast to the above three genes, calnexin (CANX) was found to increase at the mRNA 
level with increased astrocytoma grade. CANX is an ER chaperone protein that binds with 
free calcium ions. It is a critical component of the mitochondria associated membrane 
(MAM), with over 80% of it located in the MAM, along with the aforementioned STRN3-
associated protein PP2A. CANX regulates the activity of sarcoplasmic/endoplasmic 
reticulum calcium ATPase (SERCA) by acting as a calcium buffer in the MAM [59]. 
Depending on its palmitoylation status, CANX shuttles between the ER and MAM [60].  
2.6.2 GENES IMPLICATED IN METABOLISM AND MITOCHONDRIA 
 
A few monotonically changing genes identified have metabolic functions. Proteins encoded 
by these genes sit closely to each other in the mitochondria, which is responsible for 
essential cellular processes such as energy production, storage of calcium ions, and cell 
death. In recent years, there has been increased reports of the role of mitochondria in 
calcium signaling [61], which helps to connect mitochondrial metabolic genes to calcium 
signaling. Metabolic regulation of calcium in mitochondria is mediated through the effects 
of dehydrogenases. Calcium ions activate matrix dehydrogenases, increase available NADH 
and electrons for the respiratory chain, and eventually accelerate ATP production [62].  
 
NDUFB8 and NDUFB1 are two monotonically decreasing genes that encode subunits of 
respiratory chain NADH dehydrogenase complex I. Decreased expression of these proteins 
causes respiratory chain dysfunction, reduces the driving force for calcium transfer and 
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available electrons in the respiratory chain, decreasing ATP production. This observation 
may reflect a reduction of mitochondrial ATP synthesis via oxidative phosphorylation—
contributing to the Warburg Effect; as the tumor grows to more aggressive stages, the 
metabolism of proliferating tumor cells is adapted to proliferation mechanism rather than 
efficient ATP production [63]. Interestingly, the NDUFB8 gene is also found very close to 
PTEN (locus of NDUF8: chr10q 24.31 and PTEN, chr10q 23.31).  
 
ACSL4 (acyl-CoA synthetase), a monotonically decreasing gene, converts fatty acids to 
fatty esters and plays an important role in lipid metabolism. Similar to CANX, ACSL4 is 
also found in MAM, which is a critical metabolic hub in lipid metabolism [64]. Though 
normally recognized as a metabolic gene, ACSL4 regulates synaptic vesicles along axons. 
Knockout of ACSL4 in embryonic stem cells was shown to significantly reduce neuronal 
differentiation [65]. A de-differentiated neuronal state in higher-grade tumors resembles 
how neural stem cells display higher potential of proliferation and angiogenesis [66].   
 
Other mitochondrial genes involved in metabolism include ornithine aminotransferase 
(OAT), a monotonically decreasing gene that converts arginine and ornithine into 
neurotransmitters glutamate and GABA. GABA receptors and glutamate transporters have 
been reported to be down-regulated in brain tumors [67]. Another mitochondrial gene 
identified is n-myristoyltransferase 2 (NMT2) which plays a role in protein myristoylation, 
proliferation, and apoptosis [68]. 
2.7 DIRAC-BASED CLASSIFICATION IDENTIFIES ACCURATE NETWORK SIGNATURES 
FOR DISTINGUISHING GRADES 
 
The high degree of transcriptomic heterogeneity observed in increasingly aggressive 
astrocytoma tumors creates substantial variance when searching for robust molecular 
signatures between grades. Still, identifying such signatures is critical to elucidating 
mechanistic differences between more and less aggressive tumors. Network-based 
approaches such as DIRAC are advantageous for extracting signal from noise, as the 
patterns of functional groups might be less within the same phenotype than those of 
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individual genes. Furthermore, DIRAC quantifies the relationships between genes, and 
operates on these pair-wise expression patterns within networks, thereby reducing the 
impact of noisy changes in single gene expression. Using DIRAC, we compared each of the 
four phenotypes to all other phenotypes (e.g., normal brain against G2, G3, GBM; G2 
against G3 and GBM; etc.) (Figure 2.6). 
 
We were able to clearly separate normal brain tissues from G2, G3, and primary GBM. 
Furthermore, these tumors could be distinguished from each other with good accuracies (> 
80%, except 78% in the case of G3 and pGBM). In separating secondary GBM from other 
grades, however, classification signals are not as strong (average accuracy of primary GBM 
and secondary GBM vs. all other phenotypes are 86% and 77%, respectively). This 
difference in classification performance very likely reflects the fact that secondary GBMs 
are derived from lower grades and therefore share more common genomic and 
transcriptomic characteristics in their expression profiles compared to primary GBMs, 
which develop spontaneously and display more pronounced phenotypic differences from 
other grades.  
 
It was also difficult to separate primary and secondary GBMs (accuracy 69%) based on their 
transcriptomes, even though they are known to develop from separate genetic pathways [69]. 
They are indistinguishable by histology, as both share the same histological grade [70]. Both 
subtypes share a number of genomic and transcriptomic similarities such as LOH on 
chromosome 10q and deregulation of the PI3K/ATK pathway [69]. Another reason for the 
relatively lower accuracy is possibly due to the signal present from other subtypes such as 
proneural (PN), mesenchymal, or proliferative subtypes (the latter two collectively known 
as non-PN) within GBMs, which appear to be more distinct than the transcriptomic 
differences we observe between primary and secondary GBM. In terms of survival, the PN 
subtype is reported to be less aggressive than other subtypes [25]. In support of this 
hypothesis, we applied DIRAC on a subset of GBM with known PN/non-PN designations, 
and separated the proneural subtype from the rest with an accuracy of 78%. This accuracy 
being higher than for the separation of pGBM and sGBM suggests that molecular subclasses 
in glioblastomas may look more different than traditional pGBM/sGBM classes, especially 
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in the context of network behavior; hence DIRAC detected the stronger classification 
signals more easily. The best 10 network-based classifiers selected by DIRAC to separate 
tumor samples from normal brains are listed in Table 2.3. In each pair-wise comparison, we 
included different metrics (sensitivity, specificity, and accuracy) and group size information 
to demonstrate the ability of DIRAC to distinguish different grades of brain tumors (Table 
2.4). 
2.8 CONCLUSIONS 
 
We report here a systems approach to investigate molecular changes underlying astrocytoma 
pathology. Leveraging a large cohort of publicly available gene expression data sets, we 
have conducted the first meta-analysis that examines together the transcriptomes of three 
astrocytoma grades along with corresponding normal samples. We have combined 
individual gene- and network-based approaches to identify meaningful patterns of 
expression within and between different grades. The trend we observed of greater network 
dysregulation with higher grade represents a quantified measure of increasing inter-patient 
transcriptomic heterogeneity in more aggressive astrocytomas. We also identified genes that 
exhibit monotonically increasing or decreasing expression with increased grade—these 
genes are potentially reflective of shared oncogenic mechanisms among phenotypically 
similar tumors. Notably, monotonically increasing or decreasing changes in gene expression, 
parallel to increasing network dysregulation, presents a putative bridge between the known 
genetic heterogeneity of astrocytomas and expression heterogeneity at the population level, 
as analyzed in this meta-study.  
 
Additionally, we identified networks distinguishing different astrocytoma grades from 
normal as well as network markers separating between glioma grades. This work presents 
significant results that enable better characterization of different human astrocytoma grades, 
and hopefully will lead to improvements in diagnosis and therapy choices.  
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2.9 METHODS 
 
2.9.1 COLLECTION AND INTEGRATION OF TRANSCRIPTOMIC DATA 
 
Raw microarray CEL files from previous studies were compiled from the NCBI Gene 
Expression Omnibus (GEO). We used data collected from the most abundant source 
platform currently, Affymetrix HG-U133A or its complimentary version, HG-U133-Plus 2.0 
GeneChips (Affymetrix, Santa Clara, CA). Table 2.5 lists the GEO accession number, year 
of publication, and the number and grades of samples reported in each original study. 
 
A “consensus pre-processing” method was applied to the CEL files to normalize differences 
introduced by non-uniform studies and sample preparation procedures. This method is 
described in greater detail in [30] and was used in that study to demonstrate that classifiers 
performed better on novel datasets when trained on multiple, integrated, pre-processed 
datasets. Briefly, common probe sets (22,277) shared by the two platforms (U133A and 
U133-Plus 2.0) were identified according Affymetrix descriptions, and GeneChip RMA 
(GC-RMA) normalization was applied to raw expression data for these probes across all 
microarray samples [71]. GC-RMA was implemented in the Matlab Bioinformatics Toolbox 
with the threshold for presence defined based on prior studies from Affymetrix [72]. Probes 
having 0% present calls for any phenotype were removed. Following these criteria, 15,827 
probes were kept for further analysis. 
 
When converting the probe intensity matrix to a gene expression matrix, probes that mapped 
to multiple genes were eliminated to remove ambiguity. For multiple probes corresponding 
to the same gene, the maximum intensity was used. Finally, all absolute intensity values 
were replaced by their relative ranks within each array.  
2.9.2 COMPUTATION OF RANK CONSERVATION INDICES IN DIRAC 
 
For all network analyses performed with DIRAC, expression levels of genes were grouped 
into 248 human signaling networks, defined according to the BioCarta gene sets collection 
23 
 
in the Molecular Signatures Database (MSigDB) [73]. For each selected network, we used 
DIRAC to compute the expected ordering of network genes (rank template) for each 
phenotype, and we subsequently measured how closely each sample’s network ordering 
matched the phenotype-specific template (rank matching score). The rank conservation 
index, calculated by averaging rank matching scores across samples in a phenotype, 
indicates how consistently each network is ordered within a population. Averaging the rank 
conservation indices over all networks for a phenotype provided a single value estimating 
the relative heterogeneity or dysregulation of networks for that phenotype.  
2.9.3 IDENTIFICATION OF MOST DIFFERENTIALLY REGULATED NETWORKS ACROSS GRADES 
 
The difference in rank conservation indices between two phenotypes (e.g., normal vs. cancer 
or lower grade vs. higher grade) was calculated for each network. Networks were ranked 
based on the magnitude of the difference. To establish statistical significance, the original 
phenotype labels were permuted and randomly assigned to samples, and the absolute 
difference in rank conservation indices was calculated for all networks in each phenotype. 
These steps were repeated for 1,000 permutations to generate a null distribution of rank 
conservation differences, and the significance level for each difference was measured as the 
probability of observing the same fraction or higher at random. 
2.9.4 IDENTIFICATION OF MONOTONICALLY CHANGING GENES 
 
We selected differentially expressed genes (DEGs) for each adjacent pair of astrocytoma 
grades, (control vs. G2, G2 vs. G3, etc.) based on the Wilcoxon rank-sum test (P < 0.05 
after Bonferroni correction). In the intersection of these DEG sets, genes with monotonically 
increasing ranks were defined as increasing genes, and monotonically decreasing ranks as 
decreasing genes.  
 
In order to test the robustness of these monotonically changing genes, we randomly selected 
80% of all samples in each phenotype, and with this subset of samples, we tracked whether 
genes were similarly increasing or decreasing across grades as they were with the full set of 
samples. We repeated this selection process 1000 times and recorded how often the 
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identified genes appear with the same pattern. Genes that appeared at least 500 times in 
1000 permutation tests were considered as high confidence genes and used for subsequent 
analysis. 
 
In order to test the significance of the directionality of genes, the original phenotype labels 
were permuted and randomly assigned to samples, and the number of monotonically 
changing genes in each permutation was calculated for both the increasing and decreasing 
case. The procedure was repeated for 1000 times and a null distribution for the gradation of 
genes was established. A P-value for the directionality/trend of the genes was assigned 
based on the probability of observing the same number of genes at random. 
2.9.5 CLASSIFICATION OF DISEASE PHENOTYPES WITH DIRAC 
 
In addition to conservation of network ordering within a phenotype (measured by the rank 
conservation index), DIRAC can also be used to identify networks ordered differently 
(variably expressed) between two phenotypes. Rank matching scores were calculated for 
each class, and predicted class labels were assigned based on similarity of each patient’s 
individual profile to either of the two templates. Apparent accuracy for classification with 
these predicted class labels was then calculated for all networks [32]. A null distribution of 
network classification rates was generated by randomly permuting phenotype labels 1000 
times, and the significance level was measured as the probability of observing classification 
rates. To address the issue of multiple-hypothesis testing, the corresponding false discovery 
rate (FDR) was calculated for each significance level, representing the fraction of expected 
false positives at any defined cutoff [32]. We used leave-one-out cross validation to estimate 
the error rate of DIRAC-based classification for each pair of phenotypes. 
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2.10 CHAPTER 2 FIGURES AND TABLES 
 
 
Figure 2.1 Overview of approach. 
A) We minimized experimental variation due to lab effects by performing uniform pre-
processing. B) Genes that either monotonically increased or decreased in parallel with increasing 
astrocytoma grade were identified. C) Molecular signatures that can accurately distinguish 
between different grades were established using Differential Rank Conservation (DIRAC). We 
also examined broad patterns of network regulation across all astrocytoma grades. 
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Figure 2.2 Pearson-correlation matrix before and after consensus pre-processing 
The heatmaps display correlation coefficients among all samples included in this study. The axes 
represent sample numbers. In the left figure, the purple borderlines of each box delineate 
different phenotypes, which coincide with the sample batches. Samples from the same 
laboratories or studies showed higher homogeneity than other samples. On the other hand, in the 
right figure, laboratory effects are much less obvious; tumor samples across different studies or 
phenotypes all look highly correlated with average correlation coefficient increased from 0.81 to 
0.91. 
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Figure 2.3 Network-level expression heterogeneity across tumor grades 
A) Global trend of network regulation level decreases with increeasing grade. The vertical axis 
represents examined networks, while the horizontal axis represents five phenotypes. Colors 
represent rank conservation indices for each network. Light colors indicate high consistency of 
network ranking in a phenotype and the dark colors indicate large heterogeneity of networks. 
Networks in sGBM and pGBM tumors become much more heterogeneous compared to the 
normal cases. B) One-way ANOVA comparing the mean rank conservation values of different 
phenotypes. C) A list of most deregulated networks between adjacent tumor grades and their 
major biological functions. The “>” and “<” indicate the magnitude of network regulation. For 
instance, AKAP13 has a larger rank conservation index in normal samples and thus is more 
regulated in normal compared to G2. 
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Figure 2.4 Genes showing consistent dysregulation with progression 
Colors on the heatmap represent relative expression values of genes in different phenotypes. The 
vertical axis lists the differentially expressed genes and the horizontal axis lists the phenotypes. 
All expression values are normalized as the percentage of maximum expression value for the 
gene across all phenotypes. For the up-regulated genes in panel A) the maximum expression is 
either sGBM or pGBM, so we see all genes have brightest color in these two phenotypes; 
similarly the down-regulated genes in panel B) decrease their expression systematically from 
normal to GBM, and the intensity level also increases with grade.  
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Figure 2.5 Functional categories among monotonically changing genes 
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Figure 2.6 Classification accuracy with biocarta database networks 
This heatmap displays leave-one-out cross-validation accuracies of DIRAC-based classifications 
on each phenotype vs. all other phenotypes. DIRAC could distinguish more distant grades like 
normal vs. GBMs; it is especially hard to separate G3 or pGBM from sGBM.  
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CHAPTER 3 IDENTIFICATION OF PROGNOSTIC MARKERS FOR HIGH-
GRADE ASTROCYTOMAS 
 
3.1 HETEROGENEITY AND PROGNOSIS IN HIGH-GRADE ASTROCYTOMA 
 
Heterogeneity in high-grade astrocytomas (HGAs; i.e., G3 and GBM) also manifests as 
differences in clinical outcome, which are often difficult to predict. Because of this, much 
effort has been devoted to identifying subtypes within a large collection of samples. A long-
standing approach to classify HGAs is based on clinical histories of patients: primary 
tumors tend to occur in older patients, and correspond with slightly shorter survival time 
than secondary tumors [20]. Another approach by Phillips et al., utilized a set of 35 genes to 
group HGAs into three subclasses, each resembling a corresponding stage in neurogenesis. 
One subclass (proneural or PN), exhibiting longer average survival, contained neuronal 
lineage markers; the two other tumor classes (proliferative and mesenchymal, collectively 
known as non-proneural or non-PN) were enriched for neural stem cell markers and had 
short survival times [25]. 
 
This chapter presents my work on using an extension of DIRAC-based classification to 
identify networks capable of predicting subtypes with differential survival in HGA. We 
found that variable expression of an erythropoietin network, which is known to mediate 
neuroprotection through NF-κB signaling (EPONFκB), could efficiently separate HGA 
patients into two groups with a significant survival difference. The prognostic value of this 
network was enhanced when combined with an established scheme for separating HGA 
patients (i.e., proneural/non-proneural) [25]. Two classes separated by both markers differed 
more significantly than classes defined by histologically determined grades or by 
proneural/non-proneural status alone. 
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3.2 THE EPONFΚB NETWORK EXHIBITS PROGNOSTIC VALUE 
 
To further explore the effects of heterogeneity among more aggressive astrocytoma tumors, 
we aimed to identify subpopulations within combined G3 and GBM samples (HGAs) with 
different clinical outcomes. Perhaps the most clinically relevant metric to evaluate subtypes 
is patient survival; this has been previously explored for primary vs. secondary tumors and 
the proneural (PN) vs. non-proneural (non-PN) subtypes (described above). With available 
survival information from 239 patients, I found that the EPONFκB network showed 
significant prognostic value. Using a distance matrix based on the DIRAC metric (see 
Chapter 3.3 Methods), the genomic profiles of all HGA patients were grouped into two 
clusters using unsupervised clustering. Subsequent log-rank tests on the survival estimates 
of these two groups (EPOLONG and EPOSHORT, indicate longer or shorter survival times) 
gave a P-value of 1.8e-5 (corrected for multiple hypothesis testing) (Figure 3.1), 
outperforming separation by path of progression (primary vs. secondary tumors, P = 0.002). 
Besides this network, four other BioCarta-defined networks showed significant P-values in 
their respective log-rank tests (Table 3.1). 
 
I next sought to improve prognostic predictions by combining the EPONFκB marker with 
established subtyping schemes. Using the previously reported proneural signature on 
microarray samples collected and processed from GEO, PN patients can be seen to survive 
longer than non-PN patients (P = 5.7e-8) (Figure 3.1). However, the 73 patients labeled both 
as PN and EPOLONG differed from the 68 patients labeled both as non-PN and 
EPOSHORT with the highest significance (2.4e-10). This integrated method of clustering 
HGA patients also outperformed histological separation (G3 vs. GBM tumors, P = 7.7e-6) 
(Figure 3.1).  
 
Nearly all G3 specimens (20/21 or 95%) were labeled as both PN and EPOLONG, 
indicating both markers having similar powers in distinguishing histologically less 
aggressive populations. The EPOLONG subclass comprises significant numbers of both PN 
(73/161 or 45%) and non-PN (88/161 or 55%) subclasses, indicating that these two markers 
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identify different populations of patients in HGA. It is interesting to note that EPOLONG 
still contains a higher proportion of PN (45%) patients than EPOSHORT (10/78 or 13%).  
 
Involvement of the EPONFκB network in gliomas is an interesting and highly debated 
subject because of its relevance to clinical treatment.  Standard treatment of GBM with 
radiation does significant harm to the surrounding brain, resulting in significant collateral 
damage. This damage is referred to as “radiochemobrain” and results in slowing 
psychomotor skills, cognitive decline, fatigue, and loss of drive, all of which significantly 
reduce the quality of life [74]. To counteract these effects, patients are sometimes given 
hematopoetic growth factor erythropoietin (EPO) prior to and following radiation. EPO 
signaling cross-activates the anti-apoptotic transcription factor NF-κB, and mediates 
neuroprotection against oxidative stress. EPO has pleiotrophic effects on the brain including 
anti-apoptotic, antioxidative, neurotrophic, axon-protective, angiogenic, and neurogenic—
many of which are associated with neuroprotection against the side effects of radiation and 
chemotherapy [75-78]. In addition, EPO has also been shown to improve the responsiveness 
of tumors to radiation therapy in human glioma xenographs by increasing tumor 
oxygenation [79].   
 
For all the positive effects EPO is believed to have, some have argued that these same 
effects could potentially promote tumor growth. Recently, EPO signaling was shown to be 
involved in angiogenesis of human glioma cells as well as cancer stem cell maintenance 
[80]. Still, others have shown that while EPO does augment the survival of glioma cells, it is 
unlikely to appreciably influence basal glioma growth [81]. While my results implicate 
EPONFκB as a novel predictor of patient survival, it is unclear if the observed modulation 
reflects increased, decreased or variable network signaling. 
3.3 CONCLUSIONS 
 
I discovered a signature predictive of survival in HGA patients based on the gene rankings 
in the EPONFκB network. Strikingly, combining the EPONFκB network and previously 
reported signatures outperformed histology-based grading or those separated solely based on 
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proneural/non-proneural status as predictors of survival. The identification of the EPONFκB 
network as a potential prognostic factor demonstrates the utility of deriving molecular 
diagnostic signatures from multiple studies. Ultimately, the results of this analysis could 
lead to improvements in diagnosis and therapeutic decisions and ultimately enable better 
predication of clinical outcome of HGA patients. 
3.4 METHODS 
 
Time of survival (days or weeks) and subtype designations were available for 239 patients. 
The microarray expression matrix of this subset of patients was normalized as previously 
described. As an extension of DIRAC, a distance matrix was constructed for each selected 
network based on the pairwise orderings of the genes within the network. For example, if a 
network m consisted of six genes, there could be 
 
distinct ordered pairs; for a gene 
pair i and j, let X denote their corresponding expression values. If Xi < Xj or Xi > Xj for both 
patient A and B, the distance of these two patients was 0; otherwise the distance was 1. The 
direct sum of the distances for all 15 possible comparisons was then normalized by the size 
of the network, to give the final average distance of patients A and B on network m. We 
repeated this procedure for all patients to obtain a 239 × 239 distance matrix. 
 
Unsupervised clustering in Matlab resulted in two groups (linkage method: weighted 
average distance, Figure 3.2). The first split on top of the dendrogram separated the samples 
into the two largest groups (A, B). If one of the groups (e.g., B) did not contain at least 10% 
of all samples, its samples were considered as outliers and removed from subsequent 
analysis; the remaining group A was then split into two (A1 and A2) according to the next 
joint on the dendrogram. Further outlier removal and group splitting continued until two 
groups with reasonable sizes were determined. The Kaplan-Meier method was used to 
estimate the survival distributions. Log-rank tests were used to evaluate the difference 
between survival groups. To address the issue of multiple hypotheses testing, stringent 
Bonferroni correction was applied to P-values obtained from log-rank tests. 
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3.5 CHAPTER 3 FIGURES AND TABLES 
 
 
Figure 3.1 Comparison of different approaches to re-classify HGAs 
Censored data indicate the patients being alive by the end of the study. a) Survival estimates of 
two groups separated by histological grades b) by PN vs. non-PN subtype, c) by prognostic 
network marker EPONFκB, and d) by combined status of PN (non-PN) and EPOLONG (or 
EPOSHORT). The log-rank test on the combined case has a more significant prognostic value 
than existing best classification. 
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Figure 3.2 EPONFκB separates the patients into two clusters with survival difference, using 
hierarchical clustering 
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Table 3.1 Networks that can separate HGA patients into groups with statistically 
significant survival difference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BioCarta 
Network 
Survival 
Difference 
EPONFκB  1.8*10-5 
CARDIACEGF  6.8*10-3  
IL22BP  1.1*10-2 
EPO 1.1*10-2 
FIBRINOLYSIS  1.3*10-2  
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CHAPTER 4 ANALYZING PROTEOMIC DATA FROM GENETICALLY 
ENGINEERED MUS MUSCULUS STRAINS 
 
4.1 UTILIZING HIGH CONSISTENCY OF PROTEOMICS DATA 
 
As I explained briefly in Chapter 1, though proteins are the translated products of RNA, 
protein concentrations do not necessarily correlate with the amount of corresponding mRNA 
in the cell [82]. Proteomic data obtained by mass spectrometry-based analysis and iTRAQ 
[83], Selective Reaction Monitoring (SRM) [84], and the newly emerging SWATH 
technologies [85] can provide direct quantification of thousands of proteins in the cell 
simultaneously.  
The high consistency of protein measurement comes with a price, compared to gene 
expression data, which is intrinsically much noisier [86]. Protein measurement experiments 
are much more expensive and cover fewer targets compared to gene expression profiling. 
The most thorough and comprehensive protein experiments presently include only a few 
thousand proteins with fewer samples in per condition. The higher consistency, low noise 
level, and fewer measurement properties of proteomic data demand a unique processing and 
analysis pipeline that is fundamentally different from our approach to transcriptomic 
analysis in the last chapter. In this chapter, I focus on developing a framework that is 
statistically valid and sound, computationally simple and efficient and lastly, biologically 
valuable and meaningful. 
As previously stated, GBM is the most common human brain tumor and it has a high fatality 
rate; the experiments conducted in this section are also aimed at understanding more on 
brain tumor biology and developing potentially new therapies based on these discoveries. 
We aimed to query and identify dynamically perturbed modules in a progressive mouse 
model of glioblastoma, by tracking behavior changes of regulatory networks in early, 
middle and late stages in disease development through protein measurements. 
Most GBMs exhibit frequent aberrations in three prominent signaling networks: cyclin-
dependent kinase/retinoblastoma (CDK/RB), receptor tyrosine kinase 
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(RTK)/RAS/PI3K/PTEN and MDM2/p53 [87]. Retinoblastoma RB is a tumor suppressor, 
and impaired RB drives tumor progression and is associated with short survival time [88]. 
On the other hand, the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) 
protein is a member of Ras family, and activation of the KRAS gene is an essential step in 
cancer development [89]. Lastly, the phosphatase and tensin homolog (PTEN) also acts as a 
tumor suppressor gene whose loss of function leads to increased cell proliferation and 
reduced cell death [90].  
The present work develops a methodology to process and analyze proteomics data collected 
from three mouse strains, which had been genetically engineered to contain one or more 
combinations of gene mutations in the three major networks mentioned above.  Eventually, 
we hope to identify and validate potential protein targets that play significant roles in GBM 
initiation and progression, and discover potential drug targets and treatment strategies of 
GBM.  
4.2 OVERVIEW OF EXPERIMENTAL DESIGN, DATA PROCESSING AND ANALYSIS 
 
Three strains of mice, with two duplicates for each strain, were collected at four different 
time points: control (beginning of experiment), early, middle, and late. The strains were 
named TR-cre, TR-het, and TR-null, each of which had two, one, and no copies of PTEN, 
respectively (Table 4.1). Protein content was measured using iTRAQ for all four stages and 
for all three strains and a comprehensive set of more than 2000 proteins in most cases were 
quantified and recorded. The controls had no genetic mutations and served as reference 
channels for the tumor samples. Cancer samples at different time points were subsequently 
normalized against their references to obtain a relative expression level. The arithmetic 
average value of duplicate observations for the same stage was calculated to represent the 
overall protein content for that stage. After these steps of normalization and processing, we 
have 3 data points for each strain and 9 points for all strains. 
Due to the extremely small size of samples for each condition, conventional gene analysis 
tools, such as Gene Set Enrichment Analysis (GSEA), which is a computational method to 
determine whether a set of genes show statistically significant differences between two 
46 
 
biological states, phenotypes and conditions are not suitable [91]. For the current study, it is 
almost impossible to reach statistical significance if we use the Kolmogorov-Smirnov test 
chosen by GSEA. We also cannot use Top-Scoring Pair (TSP) or DIRAC, both excellent 
methods to identify simple disease classifiers, for similar reasons. The unique nature of 
proteomics data calls for a method that is computationally very simple, and at the same time 
offers statistical power even if we only have one or two samples in each condition. 
With these considerations in mind, I developed a method that groups genes into a priori 
defined sets of genes and calculates if the median of this particular set of genes show a 
difference between two cancer stages. By grouping genes into networks and calculating if 
the median expression value changes significantly as a group, the significance of networks 
could be evaluated using the Wilcoxon rank-sum test, which compares two matched 
samples to assess whether their population median ranks differ [92]. It is an alternative to 
the paired student’s t-test, without the assumption that the populations are normally 
distributed [93]. The non-parametric nature of the Wilcoxon is especially suitable for the 
present data because we have no prior knowledge on the distributions of the genes in a gene 
set.  
The manually curated gene set database I selected for data processing was the Biocarta 
pathway database, which was defined according to the BioCarta gene sets collection in the 
Molecular Signatures Database. Genes were grouped into 248 human signaling networks 
[91]. Before grouping gene expressions into BioCarta gene sets, we mapped mouse genes 
into their human orthologs according to Mouse Genome Informatics (MGI) database [94, 
95]. Gene sets having at least two genes were kept in the collection for further analysis. 
Around 2000 genes were mapped to 159, 148, 157 gene sets in TR-cre, TR-het, and TR-null 
strains respectively. 
4.3 EXAMINATION OF PERTURBED NETWORKS IN DIFFERENT STRAINS 
 
We were interested in identifying networks displaying different group behavior, as 
measured by the network median under different cancer stages. To identify the networks, I 
compared expression profiles at different time points against each other (early vs. middle, 
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early vs. late, middle vs. late) and ranked the networks according to the P-values of rank-
sum test. Networks that showed significant changes (P-values < 0.05) under various cancer 
stages were named perturbed networks. Perturbed networks could either show up-regulation 
if the network median increases, or down-regulation if the network median decreases. The 
results of up- or down-regulation varied significantly from strain to strain. 
For all three strains, we used the symbol μ to represent the median value of the gene sets, 
and μearly, μmid, μlate to represent the corresponding network medians at different time points.  
Figure 4.1 showed how different networks responded to cancer progression in the three 
cancer stages.  
Both the TR-cre and TR-null strains (Figure 4.1A and C) demonstrated an overall pattern 
of up-regulation when GBM progressed from early to middle and late stages. Higher 
expression at more advanced tumor stages usually implies more genetic activity at the 
cellular level, and could reflect the body’s counter efforts to restore the diseased cells to 
normal states. Genes involved in these correction mechanisms could be tumor suppressors 
or targets of tumor suppressors which act to prevent the tumor from advancing or promote 
immune responses in tumor [96-98]. The majority of genes being up-regulated might also be 
oncogenes or targets of oncogenes which are involved in tumorigenesis pathways and cause 
tumor cells to survive and proliferate [99-101].  Another possible reason for the observed 
differences in expression is how the raw data were normalized after initial measurement. 
However I was not able to access raw data to assess this hypothesis. .  
In contrast to these two strains, the TR-het strain displayed much lower gene expression at 
the network level when the tumor progressed to the late stage (Figure 4.1B). The reason 
that most genes are under-expressed might be that the glioma had rapidly evolved to 
glioblastoma, and extensive necrosis had occurred in the late stage. The possible presence of 
large amount of cell death and microvascular hyperplasia might help to explain the low or 
even lack of activity of most genes [102, 103]. 
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4.3.1 PERTURBED NETWORKS FROM THREE STRAINS 
 
For the TR-cre strain, I observed a total of 10 networks for which the median expression 
value increased from early to middle stage, and from early to late stage (Figure 4.2A). I also 
identified another 9 networks with up-regulated average expression in one, but not both 
cases (i.e., up-regulation from early to middle, or from early to late stage). I did not discern 
any pathways with significant changes from middle to late stage.  
The perturbed networks from The TR-het strain, in which one copy of the tumor suppressor 
PTEN was knocked out, demonstrated very different behavior from the TR-cre strain. There 
were 87 networks with μmid > μearly, but no networks showed increased μ from early to late 
stage, or from middle to late stage. The top 10 perturbed networks ranked by P-values are 
shown in Figure 4.2B. In fact, all genes showed down-regulation advancing to late GBM. 
As explained earlier, the rates of progression in different strains vary significantly from each 
other, and in this strain, a high percentage of necrosis or apoptosis in cancer tissue might 
already be present in this terminal stage. The extremely low gene expression levels did not 
reflect meaningful biological events and it is also not valid to compare progression events at 
this stage to earlier stages, or to stages of other strains, therefore the particular set of data 
was not kept for further analysis.  
 
Late stage GBM appeared earlier in the mouse strain with heterogeneous PTEN (PTEN +/-), 
but not in other two strains, which might be explained by the stochastic p53 mutation driven 
by KRAS activation. It has been hypothesized that KRAS activation would positively select 
for p53 missense mutant cells [104]. P53 tumor suppressor proteins are encoded by the 
TP53 genes, which guard and conserve genome stability by preventing genome mutation 
[105]. Gene mutations can change the resultant protein structure, resulting in effects on cell 
replication. Tumor cells that are genetically unstable may be allowed to replicate [106].  In 
fact, this gene represent one of the most frequently occurring perturbations in human tumors 
[107]. There are at least two genetic pathways leading to GBM, a de novo pathway without 
P53 mutation, and a progressive pathway with P53 mutation [108]. P53 mutations in 
gliomas coupled with heterozygous deletion of PTEN allele may imply an additive effect of 
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combined gene deficiency that drives glioma progression, therefore explaining the fast 
tumor growth in this case. Supporting this hypothesis is the finding that PTEN +/- mice with 
concomitant inactivation of CDKN1B, a key player in CDK/RB pathway, showed 
accelerated neoplastic transformation, and these mice all developed prostate cancer within 
the first three months of life [109].  
 
The TR-null mouse strain, with both PTEN alleles inactivated, displayed a more similar 
gene and network pattern to the TR-cre strain, than to the TR-het strain, with middle and 
late protein profiles showing higher network medians than early stage protein profiles 
(Figure 4.2C). The experimental results suggest that homozygous deletions at the PTEN 
locus might slow the glioma development process compared to the heterozygous deletions. 
PTEN -/- is a much rarer event in gliomas than PTEN +/-; while PTEN LOH was detected 
in 30% primary GBMs [69, 110], only 5-10% loss of both PTEN alleles were detected in 
similar cases [111, 112]. Gliomas losing both alleles of PTEN might represent a distinct 
subset of GBMs that worth more effort to investigate the mechanisms of tumor initiation 
and progression [104].  
4.3.2 SELECTION OF TARGETS FOR VALIDATION 
 
After I examined all networks in each strain, over all stages, I concentrated my efforts to 
identify the most perturbed networks appearing across multiple strains, and subsequently 
selected a subset of genes that could be validated by Western blot to confirm their 
significance. I only selected networks for which the network median either increased or 
decreased in at least 1 out 3 possible scenarios (μearly < μmiddle, μearly < μlate, μmiddle < μlate). 
This yields a total of 268 gene targets across all strains. The numbers of commonly shared 
significant genes between any two strains and among all three strains are indicated on 
Figure 4.3. Among all the 268 genes, 18 were selected based on their known roles in GBM 
progression as well as P-values associated with the networks they came from. If a gene 
appeared in more than one network, P-values for that particular gene was averaged across 
all the networks in which it appeared (see Chapter 4.4 detailed methodologies). Western 
blotting for these proteins is currently ongoing.  
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4.4 CONCLUSIONS 
 
In this chapter, I describe the development of a methodological and systematic way to 
process and analyze proteomics data, which reflect the amount of protein content present in 
cells. This project aimed to identify individual proteins and networks that were most 
perturbed when GBM developed as a result of mutations in one or more major signaling 
pathways, common to GBM. Protein profiling was done on three genetically engineered 
mouse strains and over 2000 proteins were tracked at three tumor development stages: early, 
middle and late. The TR-het strain, in which one copy of PTEN was knocked out, displayed 
faster tumor progression than TR-cre, in which both PTEN copies were kept intact and TR-
null, which lost both copies of PTEN. I aggregated related genes into gene sets and analyzed 
their collective behavior, captured by a single metric called network median (or μ) across 
stages, and assigned statistical significance based on Wilcoxon rank-sum test. The most 
perturbed networks ranked by P-values from each strain were identified. A small subset of 
genes selected from these significant networks across all strains is now waiting for further 
experimental validation to confirm their potential values in GBM initiation and progression. 
4.5 DETAILED METHODOLOGIES 
 
For each network with more than two genes, a network median across all gene components 
in the network was computed at each time point in the dynamic time series data (i.e., early, 
middle or late). For example, if a network consists of three genes, and they have expression 
values 1, 2, 3 at early stage, and the same set of genes are expressed at 5, 7, and 9 at middle 
stage, we will compare the early median value 2 with the middle median value 7. The 
statistical question set out to answer is: Is 7 significantly higher than 2 given the 
observations? The Wilcoxon rank-sum test was used to evaluate the significance and 
direction of change. 
If the question is framed in statistical language, we tested the null hypothesis (H0), which 
states that the median difference of this particular gene set under two conditions is zero, 
51 
 
against the alternative hypothesis (H1) that the median difference is not zero, and whether 
the median increases or decreases if the alternative hypothesis is true. 
For each gene expression value, |X2,i – X1,i| was calculated and the signs of the differences 
were noted. Pairs with zero differences (|X2,i – X1,i|=0) were excluded to reduce the sample 
size. Next, the absolute differences were ordered from largest to smallest and their ranks (Ri) 
in the ordering were recorded. In our example, the three absolute differences 4, 5 and 6 
received a rank of 1, 2 and 3 respectively. Pairs with the same ties received a rank equal to the 
average of their ranks.  
The test statistic was calculated as follows: 
T = ∑ 𝑠𝑔𝑛[(𝑋2,𝑖 − 𝑋1,𝑖) ∗ 𝑅𝑖]
𝑁
𝑖=1 .  
Last, T was compared with cutoff value to decide whether to keep or reject the null 
hypothesis. If the alternative hypothesis is accepted, i.e if the comparison is statistically 
significant, a score of 1 would be assigned to this test (i.e., middle vs. early). Similar 
procedures were repeated for early vs. late, and middle vs. late; scores are assigned based on 
the statistical test results. The maximum possible score for a network is 3, and this happens 
when both middle and late stages showed significantly higher network medians than early 
stage, and at the same time, the metric was also higher in late stage than in middle stage. 
After the sum of scores (possible values 0, 1, 2, 3) were calculated for all networks, the 
networks were ranked according to the sum of scores. For networks with the same score, P-
values were used to break the ties and gave them different significant levels.  
The genes in the statistically significant networks were aggregated for each strain; I found 
that a large amount of genes were shared among different strains. These genes showed their 
essential roles in GBM independent of genetic backgrounds. To make sure that all three 
strains were contributing evenly to a 250-gene list, all networks in the TR-cre and TR-het 
with scores 1 and above, and networks in the TR-null strain with scores at least 2 were 
selected for further examination. . 
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4.6 CHAPTER 4 FIGURES AND TABLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C B A 
Figure 4.1 Heatmaps of network medians at different GBM stages 
A) TR-cre strain B) TR- het strain and C) TR-null strain. Network medians are ranked from low 
to high in their respective early stage 
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Figure 4.2A Most perturbed networks from the TR-cre strain 
 
FIGURE 4.2B Most perturbed networks from the TR-het strain 
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FIGURE 4.2C Most perturbed networks from the TR-null strain 
The vertical axis indicates relative average network median μ after normalized as percentage of 
the control channel, and the horizontal axis lists the names of the networks. Early stage is shown 
as blue, middle as green and late as red bars. Most perturbed networks showed up-regulation in 
more advanced cancer stages.  
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Figure 4.3 Gene sets selected from perturbed networks 
The three circles represent perturbed networks and the gene sets in them. The three numbers 78, 
93, and 177 represent common genes shared by two adjacent strains, and 77 genes are shared 
across all three strains. The numbers are not proportional to the area in the Venn diagram.  
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 RB KRAS PTEN 
TR-cre inactivated activated +/+ 
TR-het inactivated activated +/- 
TR-null inactivated activated -/- 
Table 4.1 Combinations of gene knockouts for different mouse strains 
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CHAPTER 5 RECONSTRUCTING LIVER METABOLIC MODEL FOR MUS 
MUSCULUS 
 
In this chapter, I describe my work in building the first liver metabolic models for mouse. In 
order to reconstruct metabolic models in a tissue-specific context, we need to start with a 
functional generic model, which contains information for all reactions and metabolites in a 
generic cell. From there, we look for evidence of which genes and reactions exist in a liver 
cell and remove reactions without such evidence. Therefore this chapter is divided into two 
parts: first, examine and refine genome-scale models for mouse, and second, build liver 
models out of the generic mouse model. 
5.1 REFINING GENOME-SCALE METABOLIC MODELS FOR MUS MUSCULUS  
 
5.1.1 RECONSTRUCTION OF GENOME-SCALE METABOLIC MODELS 
 
As I explained in the introduction, metabolic analysis can offer a distinct perspective and 
valuable insights into the molecular mechanisms of a particular organism. A metabolic 
model is a mathematical representation of the biochemical pathways in the metabolic 
network of an organism. Each reaction consists of metabolites, genes, transcripts, proteins 
and the network consists of inter-connected reactions. For a certain organism, 
physiochemical constraints (e.g. conservation of mass) are added after the metabolic 
network has been assembled. A stoichiometric matrix S, of size m × n, where m is the 
number of participating metabolites and n is the number of corresponding reactions in the 
network, is used to describe the relationships between metabolites and reactions. Each 
element Si,j in the matrix represents the stoichiometric coefficient of the metabolite in the 
corresponding reaction. Constraint-based modeling typically analyzes metabolic fluxes at 
steady state (S × v = 0, where v is the flux distribution vector containing flux values for each 
reaction)—i.e. zero net change in metabolite concentrations. Other constraints such as upper 
and lower reaction bounds (maximum flux vmax and minimum flux vmin) and reaction 
reversibility, when known, are placed on each reaction. The resulting model is then ready to 
be used for phenotype simulations using various constraint-based reconstruction and 
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analysis (COBRA) methods [113]. When the metabolic biochemical pathways are integrated 
with whole genome sequences, a genome-scale metabolic model is constructed. 
The first genome-scale reconstruction of metabolic networks, which appeared in 1999, was 
for Haemophilus influenzae Rd [114]. Since then, different methods for building and 
analyzing metabolic networks of genome-scale models have been established for all 
branches of life [115, 116]. 
Because disease results from the malfunction of one or more biological networks, diseased 
states show aberrant metabolic networks as compared to the normal state. Metabolic genes 
controlling reactions in the networks exhibiting abnormal expression levels can be identified 
in gene expression data. Tracking the activities of these significant genes or biomarkers can 
help us distinguish diseased vs. normal states. Therefore, metabolic reconstruction is an 
effective approach to infer biomarkers that may represent critical nodes in the perturbed 
networks, leading to insights into new drug treatment targets. These new therapies could 
either be used to convert the diseased network back to a normal state or permit the specific 
killing of the diseased cells [117]. 
5.1.2 METABOLIC RECONSTRUCTIONS FOR MUS MUSCULUS AND HUMAN 
 
The mouse serves as a fundamental experimental animal to mimic human diseases to 
improve understanding of the causes and progression of disease symptoms [118-120]. In 
this chapter, I examine the existing efforts to reconstruct genome-scale mouse metabolic 
models and made necessary changes to improve and refine its functionality. 
The largest and most comprehensive mouse metabolic reconstruction to date contains 1,415 
metabolic genes accounting for reactions in eight cellular compartments (cytosol, 
mitochondrial, extracellular, golgi, lysosome, ribosome, and nucleus) [120]. Despite these 
capabilities, the current model lacks the ability to simulate several essential metabolic 
functions. For instance, simulations of the current mouse model failed to produce any of the 
nine non-essential (should be synthesized de novo by mouse) amino acids (AAs) when 
provided with glucose and other inorganic metabolites. Synthesis of non-essential AAs 
within the body without supply in the diet represents a fundamental ability of mammalian 
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metabolism and the inability of the model to complete this implicates missing reactions in 
major metabolic pathways. 
Dealing with these limitations, missing links in this mouse metabolic network model had to 
be identified. The improved model needs to pass a universal functional test, which includes 
functional central metabolic pathways (glycolysis, TCA cycle, pentose phosphate pathway), 
a functional fatty acid synthesis pathway (from acetyl-CoA to palmital-CoA), and 
demonstrates the capability of synthesizing non-essential amino acids, nucleotides and key 
membrane lipids from glucose. 
Released in 2007, Homo sapiens Recon 1 is a comprehensive literature-based genome-scale 
metabolic model that accounts for the functions of 1496 genes, 2766 metabolites, and 3311 
reactions. [121]. In 2013, Recon 2 which represents a “consensus metabolic reconstruction” 
and the most comprehensive representation of human metabolism was released. Compared 
to its predecessors, the reconstruction has improved its functional and topological features, 
doubled its reaction numbers and included many more unique metabolites [122]. Due to the 
high sequence homology between human and mouse (range around 85%~92%), a mouse 
metabolic model was published in 2010; the model was built by searching for genes 
homologous to Human Recon 1 within the mammalian genome [120]. The draft model 
contained 1,415 metabolic genes and was termed (iMM1415). This model represents the 
largest and most comprehensive mouse reconstruction to date. Unlike the corresponding 
human model, there had been limited efforts extending this mouse metabolic model to better 
our understanding of mouse metabolism. Specifically, there has been no study focusing on 
building tissue-specific models for the mouse. Moreover, the current mouse models still 
lacks some fundamental metabolic capabilities as a generic model (Table 5.1).  
5.1.3 IDENTIFYING LIMITATIONS AND INACCURACIES IN THE GENERIC MODEL 
 
I obtained an updated version of the generic mouse model from the author of iMM1415. 
This revised model consists of 1752 transcripts representing 1361 unique genes (iMM1361). 
The reduction in the number of genes compared to iMM1415 is due to removal of some 
genes being human genes in the former model. 
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A universal metabolic test was used to determine whether iMM1361 possesses the basic 
functionality of a cell. Metabolites tested include precursor metabolites in central metabolic 
pathways such as glycolysis and the TCA cycle, non-essential amino acids (AA), 
nucleotides, palmital-CoA, cholesterol, and several membrane lipids. This model is 
incapable of producing any of the non-essential amino acids and the nucleotides and certain 
lipids (Table 5.1). The production of non-essential amino acids were tested in the following 
condition: the networks were allowed to uptake glucose and inorganic compounds such as 
oxygen, carbon dioxide, phosphate, and other ions. All other organic compounds besides 
glucose were constrained to be efflux only. The production of nucleotides was tested in the 
same medium. 
 
Linear programming approaches (flux balance analysis (FBA) or flux variability analysis 
(FVA)) in the COBRA toolbox were  used to solve the equation S × v = 0 given upper and 
lower bounds on the metabolite concentrations. FBA gives a particular flux distribution, 
while FVA gives flux boundaries of the reactions which could equally return equivalently 
optimal solutions to maximize or minimize the objective function [113].   In each test, the 
objective function was to maximize the production of the selected metabolite (i.e., any of 
the AA or nucleotides).   
 
I traced the amino acid formation pathways and found two missing reactions involved in 
glutamate metabolism (BiGG ID 2169419, 2169428). These two reversible reactions 
synthesize glutamate from α-ketoglutarate with glutamate dehydrogenase. Two metabolic 
genes (EC number 1.4.1.2 and 1.4.1.4), have been added to the model accordingly. The 
existence of the reactions and related genes has been validated in literature [123, 124]. With 
the addition of these two reactions, the model is capable of producing all non-essential AAs, 
nucleotides and necessary lipids. 
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5.2  RECONSTRUCTION OF TISSUE-SPECIFIC MODELS FOR MUS MUSCULUS 
 
5.2.1 NECESSITY TO BUILD TISSUE-SPECIFIC MODELS 
 
Complex multicellular organisms such as mouse or humans consist of many distinct tissues 
and cell types, each only expressing a fraction of the metabolic genes encoded within the 
genome [121]. To accurately track changes in active genes for specific tissues involved in 
the initiation and progression of certain diseases, we need to study these diseases in a 
tissue/organ-specific context. Previous efforts have reconstructed and analyzed individual 
tissue models [125-128] for humans, while a few others have furthered the efforts by 
simulating the metabolism of a larger system containing multiple tissues or cell types and 
taking into account the interactions among them [129, 130]. Specifically, Recon 1 was 
tailored to describe metabolism in three human cells: adipocytes, hepatocytes, and myocytes. 
These three cell-specific networks were integrated using a novel multi-tissue type modeling 
approach to simulate known metabolic cycles and study diabetes [131]. 
Though a lot of efforts have been devoted to build tissue-specific models for humans based 
on human recon 1 and recon 2, there had been very few studies focused on building 
analogous tissue specific models for mouse. Our study aimed to create the first liver specific 
mouse models based on our improved and refined version of the generic model, presented in 
Chapter 5.  The main focus for this study is the liver, for which the major metabolic cell 
type is the hepatocyte. The liver represents an essential metabolic organ in which glucose 
circulates through after it enters the blood; it uses alternative sugars as energy sources, 
completes the urea cycle, and produces urea from nitrogen. Many metabolic disorders and 
diseases such obesity, diabetics, and fatty liver diseases all involve the crucial body organ 
liver. In this chapter of my dissertation, I present the reconstruction of two liver-specific 
metabolic models for mouse, with one for the normal (control) strain and one for mouse 
strains with diabetes. These two models were compared physiologically to infer metabolic 
pathways that were most impacted by the onset of diabetes. 
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5.2.2 DIABETES AND DIET-INDUCED OBESITY IN HUMANS 
 
Diabetes mellitus is a chronic disease that typically requires intensive, lifelong management. 
According to the International Diabetes Federation as of 2011, 336 million people 
worldwide have type 2 diabetes, resulting in 4.6 million deaths each year, or one death every 
seven seconds [132]. In the United States, 12% of American adults, and >25% of those over 
the age of 65, are affected. Currently, there is no cure for diabetes. What exacerbates the 
problem is that diabetes increases the risk of heart disease, stroke, and microvascular 
complications such as blindness, renal failure, and peripheral neuropathy [132]. Type 2 
diabetes mellitus (T2DM) makes up most of diabetic cases. Reported causes to this disease 
include lifestyle factors such as age, pregnancy, obesity, and genetic factors. 
Over the past 50 years, we have witnessed a dramatic increase in T2DM. The massive 
increase in diabetes incidence is not due to genetic changes; rather, it is largely a 
consequence of the concomitant increase in obesity [133]. It is widely recognized that 
defective insulin secretion caused by reduced β cell function is the key problem in T2DM.  
Insulin transports glucose entering the blood stream to the muscle, fat, and liver cells—
where it can be used as energy sources to the body. Obesity lowers insulin sensitivity in 
peripheral tissues; then, to compensate for this, β cells up-regulate insulin secretion. The 
degree to which they are able to do so determines whether or not the individual develops 
diabetes [134]. Obesity and related T2DM are generally accepted as a consequence of 
dietary imbalance rather than genetically programmed diseases [135]. They are modulated 
by lifestyle and diet, which induce pathophysiological changes throughout the body [136]. 
Several genes implicated in T2DM have also been identified, but how exactly they interact 
with each other remains enigmatic.  
5.2.3 GENETIC STRAINS OF OBESITY AND DIABETES OF MOUSE 
 
As I introduced earlier in Chapter 5, the mouse is a primary mammalian model system for 
genetic research. With available inbred knockout mouse strains, the mouse metabolic 
reconstructions could be examined for their phenotype prediction capabilities [137].  It is 
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essential that the rodent models imitate particular characteristics of human disease and 
resemble the genetic changes in diabetic and obese patients.  
Established genetic strains of obesity and diabetes include db/db mice, ob/ob mice, Zucker 
diabetic fatty rats, etc. [135]. These models are obtained by inducing mutations in certain 
chromosomes. As previously mentioned, human diabetes and obesity are largely diet-
induced, chronic consumption of a high-carbohydrate, high-fat diet by normal rodents 
provides an adequate rodent model to study these diseases of interest [135]. 
A common inbred strain of laboratory mice, which is usually used as a background for these 
genetic variants is C57BL/6 ((often referred to as “C57 black 6” or “black 6”). Its popularity 
is largely due to the availability of congenic strains, easy breeding, and robustness. Two 
distinct substrains of the B6 mice, C57BL/6J from Jackson Laboratories ("J") and 
C57BL/6N from NIH ("N") were later developed, distributed, and maintained by different 
investigators [138, 139]. Though externally similar, these two sub-strains are genetically 
distinct from each other.  I built reconstructions exclusively for the C57BL/6J strain, though 
the protocol could be easily extended to other mouse strains, if needed later. Subsequent 
analysis of these models will provide us insights into the pathophysiology of the disease 
(e.g., diabetes) and selection of the potential therapeutic targets.  
5.2.4 ALGORITHMS FOR AUTOMATIC RECONSTRUCTION OF TISSUE-SPECIFIC MODELS 
 
Earlier in this chapter, I presented my improvement of the generic mouse model, which laid 
a solid foundation on which to build the liver-specific reconstructions. Having picked the 
mouse strain (B6) and decided on the disease to study (diabetes), the next step was to select 
an algorithm, a computational method to decide which reactions from the generic, whole 
body model should stay in the final liver model, and which should not, based on gene 
expression data that tell us which genes are expressed in the tissues.  
 
The model-building algorithm (MBA) by Jerby et al. addresses this challenge [128]. It 
derives a tissue-specific metabolic model from a generic one based on network integration 
with various molecular data sources. First, core reactions are inferred from gene expression 
data. They are further split into two groups: reactions with high and moderately high 
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likelihood reactions (CH and CM). The final optimal model will include all CH reactions, a 
maximal number of CM, and a set of gap filling reactions.  
 
To determine whether to remove or keep a certain reaction from a given iteration, the 
potential reactions were scanned in random order. The scanning order of candidate reactions 
affects the resulting model. Therefore, the algorithm is executed 1000 times with different, 
random pruning orders to construct multiple candidate models. These candidate models 
were further compared and analyzed to reach the final viable and consistent model. 
 
However, the accuracy of the optimal model is limited by the fact that even 1000 iterations 
could only cover a small portion of the large space of possible orderings.  Another problem 
with MBA is its modeling building process is very time-consuming. A more deterministic 
and simulation-independent ranking of potentially removable reactions could help to 
accelerate model building time dramatically [140]. Our laboratory recently developed a 
method called metabolic Context-specificity Assessed by Deterministic Reaction Evaluation 
(mCADRE) (Figure 5.1), which fulfills the same purpose as MBA, but with two additional 
advantages: first, non-core reactions are ranked according to their own expression evidence 
and connectivity map to other reactions in the network and then removed in the inverse 
order of this ranking [140]; second, the performance of mCADRE was significantly better 
than MBA. Its performance was evaluated by reconstructing a human liver model and 
comparing it with the model built using MBA. mCADRE demonstrated improved model 
functionality, and significant shorter reconstruction time (under the same configuration, 
mCADRE required only about 10 CPU-hours while MBA took approximately 10,000 CPU-
hours) [140]. 
5.2.5 DATA COLLECTION AND PROCESSING FOR BUILDING TISSUE-SPECIFIC MOUSE 
MODEL 
 
Microarray gene expression data were used to identify highly expressed or non-expressed 
genes for both normal and disease models. For each model, I compiled raw microarray CEL 
files from previous studies as cataloged in the NCBI Gene Expression Omnibus (GEO). I 
focused strictly on data from the microarray platform Mouse Genome 430 2.0 (Affymetrix, 
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Santa Clara, CA). Table 5.2 lists the number of samples and studies collected for normal 
and diabetic liver. For the control tissue model (Table 5.2A), I included only gene 
expression data for the B6 mouse strain. Within this strain, I excluded gene expression 
profiles with genetic modifications on the B6 genotype (transgenic or knockout models, 
models with gene mutations etc., because these changes may directly affect their phenotypes 
(e.g., weight gain), thus defeating our purpose of building a “control” strain for mouse).  For 
the disease (i.e., diabetes) model (Table 5.2B), I only included expression obtained from F2 
mice inbred from a diabetic strain and B6. 
In order to read the probe sequences from the Affymetrix platform (i.e., Mouse Genome 430 
2.0), I obtained two relevant files: first, a FASTA file containing the probe sequence 
information [141], and second, the CDF library file which specifies which probe set each 
probe belongs to on the selected GeneChip array [142]. With these two files ready, I used 
the “affyprobeseqread” command in Matlab Bioinformatics Toolbox to obtain the structure 
containing the probe set IDs from the selected mouse platform. 
The “consensus pre-processing” method which I used in Chapter 2, was again applied to 
process CEL files to normalize differences introduced by non-uniform studies and sample 
preparation procedures. This method is described in greater detail in [30]. This algorithm 
returned us with normalized gene expression files, and the associated Presence/Absence 
calls and the corresponding probes for each gene feature.  
The metabolic mouse reconstruction identifies genes by Entrez Gene IDs, rather than by 
probe set IDs from consensus pre-processing. It was necessary to find the correspondence 
between two sets of identifiers and filter out probes without matched gene IDs. The BioMart 
software, which offers the free service of converting between different formats of gene 
identifiers, was used to complete the gene mapping task [143]. I started with 45101 probe 
sets on the selected mouse platform and ended with 20963 genes after these steps.  
5.2.6 GENERATION OF TISSUE SPECIFIC MODELS USING MCADRE 
 
As explained earlier, mCADRE is a very efficient and robust automatic reconstruction 
algorithm that prunes reactions with insufficient evidence to stay in the tissue models. A few 
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key metrics were calculated and tuned before and during the pruning process, which 
influenced heavily the final reactions included in the tissue model. Before all potential 
reactions could be lined up for examination, they needed to be ranked properly.  
For each gene, a ubiquity score U(g) was calculated by quantifying how often a gene g is 
expressed across all samples of the tissue of interest.  A ubiquity score ranges from 0 to 1 
and is a parameter indicating the prevalence of the gene in the tissue.  
The expression-based evidence Ex was calculated for each gene-associated reaction by 
assigning specific rules to combine and integrate the ubiquity scores of multiple genes 
involved in the reaction [140]. Ex was used to rank reactions from high to low, and reactions 
with sufficiently high Ex (Ex >= 0.9 in my study) were defined as the core reaction set. For 
non-core reactions with low expression-based evidence or reactions without associations to 
known metabolic genes, a network topology metric connectivity-based evidence Ec was 
introduced to rank them. A third reaction ranking metric, confidence level scores El which 
provides literature support to each reaction in the generic mouse model, was added to 
further distinguish reactions with similar expression and connectivity-based scores. The 
details and formulae of ranking reactions followed from the original mCADRE paper and 
were described in detail in [140]. 
After the reactions were ranked, they were examined in order to determine whether they 
should be kept in the tissue model. Non-core reactions could be pruned from the generic 
model, if their removal affected fluxes through the core reaction set, or resulted in failure to 
produce key metabolites from glucose. A list of key metabolites was compiled based on 
literature evidence and included principle metabolites common to all cellular models [131]. 
These metabolites included precursor metabolites from central metabolic pathways 
(glycolysis, TCA cycle, pentose phosphate pathway), amino acids, lipids, and nucleotides. 
Successful production of these products from glucose represents the most essential 
metabolic functions that are common to both the generic model and to the tissue model. 
Therefore, this basic functionality test was carried out in the generic model before the 
pruning started, and was also examined for each non-core reaction, to make sure the 
removal of the candidate reaction would not result in the failure of this test. 
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For core-reactions, I followed suggestions from the original mCADRE paper to allow for a 
flexible core reaction set, which would increase tissue-specificity of metabolic pathways. 
The principle behind a flexible core is that, when there is enough strong evidence saying a 
reaction should not be included, even a core reaction could possibly be removed. The 
parameter representing the ratio of inactivated core reactions to inactivated non-core 
reactions was tuned to balance sensitivity and specificity: a low ratio keeps more reactions 
with strong positive evidence, while a high ratio removes more reactions with strong 
negative evidence [140]. This parameter was selected to be 0.2 for both the control and 
disease liver models. For the control model, if the ratio was increased to higher values (from 
0.2-0.5 to 0.5-0.8), another 18 core reactions related to chondrointin/heparan sulfate 
biosynthesis would be excluded from the model, however, there is literature evidence stating 
these reactions should be present in mouse liver [144]. For the disease model, increasing the 
ratio would also exclude partial heparin biosynthesis pathway, so 1/5, which means for each 
core reaction to be removed, at least five non-core reactions need to be removed at the same 
time, was chosen for both models as the optimal balance to keep reactions with strong 
positive evidence, and exclude reactions with strong negative evidence.  
After these parameters were experimentally determined, mCADRE was used to create the 
preliminary versions of normal-liver and diabetes-liver.  
5.2.7 ADDING FUNCTIONALITY TO IMPROVE SPECIFICITY 
 
The models coming straight out of mCADRE only possess the universal functionality for all 
cell types; they lack the specific characteristics unique to each cell type. For example, the 
hepatocytes are capable of generating glucose from various non-carbohydrate carbon 
substrates such as pyruvate, lactate and glycerol, through a process called gluconeogenesis. I 
collected a comprehensive set of liver specific functionality tests from various research 
studies and implemented them in both liver models.  
Gluconeogenesis Tests 
The hepatocyte is responsible for a wide range of biochemical functions and 
gluconeogenesis is amongst the most important responsibilities of hepatocytes. It is the 
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primary mechanism to maintain blood glucose level in mammals. The main gluconeogenic 
precursors are lactate, glycerol and two glucogenic amino acids (alanine and glutamine). 
These four precursors account for more than 90% of the overall gluconeogenesis [145]. 
Other less important gluconeogenic substrates include additional 11 glucogenic amino acids 
and 5 amino acids that are both glucogenic and ketognic. Another key substrate is pyruvate, 
which interconverts with lactate in the Cori Cycle and is the first designated substrate of the 
gluconeogenic pathway. The hepatocyte network was tested for its ability to produce 
glucose from all of above-mentioned substrates. Gluconeogenic simulations with the 
reactions, substrates and maximized glucose production were listed in Table 5.3. It is worth 
mentioning that metabolic simulations initially showed that only 19/21 substrates could 
generate glucose. The two substrates threonine (Thr-L) and methionine (Met-L) failed to 
produce glucose when they were provided to the network. We further examined the original 
generic metabolic network and similar problems also existed there. The problem was traced 
to the need to transport propanoyl-CoA, which is produced in the cytosol by an intermediate 
product 2-Oxobutanoate in threonine and methionine degradation, to mitochondria, so 
propanoyl-CoA could be used by downstream reactions to produce other essential 
intermediates in the metabolism pathway. By identifying the gap and completing the 
pathway, the addition of missing reactions further refined the metabolic network in the 
generic mouse model. 
Ketogenesis tests 
Another key function of hepatocytes is their capability to produce ketone bodies 
(acetoacetate and β-hydroxybutyrate) in the mitochondria in response to low glucose 
concentration in the blood. Carbohydrates are usually the first sources for energy, but when 
carbohydrate stores are exhausted, cells turn to fatty acids to generate energy. Ketone bodies 
are produced from the β-oxidation of fatty acids. The production of acetoacetate and β-
hydroxybutyrate were tested using Stearoyl-CoA (C18:0) as a model fatty acid. The 
simulations can be found in Table 5.4A. 
Alternative sugar metabolism tests 
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The liver is able to utilize alternative sugars other than glucose as energy sources [146].  I 
tested the ability of the hypatocyte networks to produce ATP from fructose, galactose and 
mannose. These three sugars were chosen to demonstrate the functionality of the network 
because all of them were metabolized primarily in the liver [147-149]. The simulations 
showed that the alternative sugar sources could produce the same amount of ATP on a 
molar basis as glucose (22.8 ATP/mol). The simulations can be found in Table 5.4B. 
Amino acid degradation, ammonia and ethanol detoxification tests 
Three degradation simulations were also tested on the liver metabolic networks: ammonia 
detoxification, ethanol degradation, and amino acid degradation. Ammonia is a by-product 
of amino acid metabolism. The amino group is removed and converted to ammonia-NH3, 
which is a toxic compound and is converted to urea in the urea cycle. Eventually urea is 
eliminated from the body through the kidneys. I simulated the ammonia detoxification 
process by allowing for glucose uptake, optimizing for ammonia uptake, and the both liver 
models were able to convert ammonia into urea. Alcohol was metabolized first to 
acetaldehyde and then to acetate, which enters the Krebs cycle and eventually broken down 
into carbon dioxide and water. Similar to alcohol, amino acids could also be oxidized to 
CO2 and H2O to generate energy. The energy produced from amino acid accounts for 10 to 
15% of all energy in the whole body [150]. The amino acids were first converted to 
ammonia and then enter the urea cycle, where they are converted to urea for excretion. 
Therefore, amino acid metabolism is intimately intertwined with ammonia and ethanol 
degradation. The simulation details of these three catabolic processes are listed in Table 
5.4C. 
Glycogen and cholesterol production tests 
The last set of functionality tests is glycogen and cholesterol production. In liver cells, extra 
glucose is mainly stored as glycogen and functions as one important form of long-term 
energy storage. The inter-conversion between glucose and glycogen is as follows: when the 
body needs energy, glycogen is rapidly broken down into glucose-6-P and then enters 
glycolysis pathway, providing the cell with source of energy. When the glucose level in 
blood is high (e.g., after a carbohydrate-containing meal), glycogen synthesis is activated to 
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store extra glucose. The liver also synthesizes large quantities of cholesterol, which is an 
essential component of lipid membranes. Glycogen and cholesterol production from glucose 
were tested in the liver models in a manner similar to the precursor tests in Chapter 6.6 and 
listed in Table 5.4D. The hepatocyte network could not synthesize glycogen from glucose at 
the beginning. The problem was traced to a missing transport reaction, which is responsible 
to bring Tyr-ggn (a primer for glycogen synthesis) from outside of the cell to the inside.  
A total of six reactions were added to both liver models in an attempt to improve tissue 
specificity. The reactions and their associated genes and simulations are summarized in 
Table 5.5. 
5.2.8 MANUAL CURATION OF LIVER SPECIFIC BIOMASS FUNCTION 
 
The biomass reaction for the liver models was manually curated based on the published 
molecular content of the hepatocytes. The relative content of protein, lipids, carbohydrate, 
glycogen, water, and nucleotides is listed in Table 5.6 and Figure 5.2. As expected, the 
liver cells contain a large portion of protein (52%) because their role in synthesis and 
storage of proteins. Either mouse or rat was used to define the proportion of each nutrient 
whenever they were available; in the absence of direct experiment measurements collected 
for mouse or rat liver, published data for human was used to define the cell composition.   
The protein proportion in the cell consists of 20 amino acids. The total amino acid content in 
the liver cell is further broken down in Table 5.7A. The values collected are measured in 
nmol per gram of liver tissue. In order to obtain the coefficients for the biomass equation, 
the values went through sequential calculations and eventually were converted to mmol per 
gram of dry weight of cell tissue.  
The lipid distribution of the mouse liver cell including phospholipid, cholesterol, and 
triglycerols were also curated from different studies for mouse or rat (Table 5.7B). The 
nucleotide composition of mouse liver cells was adapted from reported values measured for 
generic mouse cells (Table 5.7C).   
After the molecular content of a liver cell was properly defined according to published data, 
the generic biomass function was replaced by the corresponding tissue-specific biomass 
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equation to reflect the objective of a hepatocyte cell. I assumed that the disease cell and the 
normal cell have identical objectives to utilize the nutrients to grow and reproduce. In both 
types of cells, they were given a finite amount of glucose, essential amino acids, and fatty 
acids. Inorganic compounds and ions were not constrained. The relative amounts of each 
nutrient were largely adopted from [151]. After setting the biomass functions in both models 
as the objective function and maximizing for biomass production, a normal cell and a 
diabetic cell were found to have a maximized biomass flux of 0.0907 and 0.0977 mmol/g 
dry cellular weight (DCW) respectively. 
5.2.9 DISEASE MODEL VS. CONTROL MODEL 
 
After implementing appropriate tissue functionality tests to normal-liver and diabetes-liver 
and accounting for liver cell biomass changes, the two models were finalized and their 
characteristics are shown in Figure 5.3. Normal and disease liver models share a large 
number of reactions as well as the genes associated with the reactions. There are 112 
reactions (4.68%) and 29 genes (2.08%) unique to the diabetic metabolic model. These 29 
genes that were overexpressed only in the diabetic patients were further analyzed to reveal 
their potential association with diabetics. Using MetacoreTM [152], a bioinformatics online 
tool for pathway analysis,  I analyzed how the input gene list intersects with Gene Ontology 
(GO) biological processes classification, and calculated the statistical significance of the 
intersection using a hypergeometric distribution [153]. The top three most enriched 
processes are: phosphagen and phosphocreatine metabolic process (P-value 5.00e-7), L-
fucose metabolic process (P-value 4.16e-7) and long chain fatty acid metabolic process (P-
value 8.32e-7). The phosphagens are energy storage compounds that can supply energy 
needs at a high rate. Phosphocreatine is one of the eight phosphagens and the most 
extensively studied phosphagen system [154]. They could synthesize ATP and decrease 
blood glucose content [154, 155], and having elevated levels of phosphagen-related genes 
may imply the body’s effort to restore the high blood glucose level to normal. Similarly, 
impaired and dysregulation fatty acid metabolism has been reported for obesity, insulin 
resistance and T2DM [156, 157]. In diabetic cases, reduced insulin sensitivity in the liver 
promotes de novo fatty acid synthesis, and increased fats flow to the liver peripheral tissues. 
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Both effects cause excessive accumulation of hepatic fatty acids in the liver and eventually 
contribute to the development of fatty liver [157].  
On the other hand, there are 37 reactions and 19 genes that showed evidence of presence 
only in normal liver cells, but not in diabetic liver cells. MetacoreTM was again used to 
characterize the genes. The top three most enriched GO processes for under-expressed genes 
are thiamine metabolic process (P-value 1.51e-4), pyrimidine-containing metabolic process 
(P-value 4.44e-3), and vitamin metabolic process (P-value 7.37e-3). Thiamine is a vitamin 
that plays a critical role in glucose metabolism [158]; it is known to be involved in the 
conversion of carbohydrates to glucose, and reduced thiamine metabolism may be due to the 
quick consumption and depletion of thiamine in diabetic patients as  a result of high glucose 
metabolic activity.  
Using MetacoreTM, I constructed a protein-protein interaction network using the gene 
products of the combined sets of over-expressed and under-expressed genes (Figure 5.4). 
The proteins either interact directly with each other (e.g., KCRM interacts with NCX1) or 
two proteins in the candidate lists interact with a common protein outside the candidate lists 
(e.g., both NCX1 and PCD2 interact with Carveolin2). The network consists of two sub-
networks; a small one consists of two seeding genes and a larger one containing seven 
candidate genes. Both genes in the 2-gene network have been well known for their 
association with diabetes. The malic enzyme 1 (ME1) is a key regulator of fatty acid 
synthesis pathway and is highly susceptible to Type 2 diabetes [159]. It has been validated 
that ME1 is a causal gene in for diabetic traits and genetically engineered mouse model with 
ME1 knocked out were resistant to both diabetes and obesity development [160, 161]. 
Similarly, the mitochondrial branched-chain aminotransferase 2 (BCAT2) showed reduced 
expression in obesity and states of insulin resistance, which coincides with our finding that 
BCAT2 was under- or not expressed in diabetic mice [162].  
Genes in the larger network also have supporting literature proving their established 
relationship with diabetes; for instance, the sodium-calcium exchanger isoform 1 (NCX1) 
plays a key role in regulating cytoplasmic calcium required for insulin secretion [163], while 
vesicular monoamine transporter type 2 (VMAT2) is highly expressed in beta cells in the 
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pancreas and it has been used as a marker of sympathetic nerve terminals to quantify the 
amount of nerve loss from the islets of diabetic rats [164, 165].  
5.3 CONCLUSIONS 
 
In this chapter, I presented my work on the first liver model reconstruction for normal and 
diabetic mice. I started with improving and refining the state-of-art generic metabolic model 
for mice (Chapter 5.1), and then comparing and choosing the most suitable algorithm for 
reaction selection, eventually I successfully created relevant working liver models which 
possess the basic cell functions as well as liver-specific functions such as gluconeogenesis. 
This project ended with connecting relevant gene products to create a protein-protein 
interaction network. This protein-protein interaction network provides a valuable and 
comprehensive map to demonstrate connections among genes susceptible to diabetes, either 
being up- or downregulated. The genes and reactions unique to the normal-liver and to 
diabetes-liver demonstrated key metabolic differences between these two states, and provide 
a good starting point to better understand the metabolic pathways and mechanisms in 
diabetes, and  to identify potential therapeutic targets for diabetic patients.  
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5.4 CHAPTER 5 FIGURES AND TABLES 
 
 
Figure 5.1 The tissue model building method (adapted from [128]) 
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Figure 5.2 Hepatocyte cell composition 
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Figure 5.3 A) Reactions and B) genes in the final versions of normal and diabetes liver. 
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Figure 5.4 Interactions among diabetic-related genes 
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Name of metabolites Number of 
metabolites 
Category 
Alanine, arginine, asparagine, aspartate, 
glutamine, glutamate, glycine, proline, serine 
9 Non-essential amino acid 
ATP, CTP, GTP, UTP, dATP, dCTP, dGTP, 
dTTP 
8 Nucleotide 
Ceramide, phosphatidylethanolamine, 
phosphatidylserine 
3 Lipid 
Table 5.1:  list of metabolites current mouse model fails to produce 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79 
 
Authors of study 
(Year, GSE number) 
GSM sample numbers Number of 
samples in 
each study 
Ackert-Bicknell et al (2006, GSE 5959) 
[166] 
GSM138289 to GSM138291 3 
Khetchoumian et al (2007, GSE9012) [167] GSM228786 to GSM228790 5 
Kozul et al (2008, GSE9630) [168] GSM243352 to GSM243410 59 
Tijet et al (2006, GSE 10082) [169] GSM254871 to GSM254873 
GSM254877 to GSM254883 
254885 
11 
Hughes et al (2009,GSE11923)[170] GSM301348 to GSM301395 48 
MacLennan et al (2009, GSE12748) [171] GSM319519, GSM319609 and 
GSM319903 
3 
Vollmers et al (2009, GSE13060) [172] GSM327055 to GSM327129 24 
Vollmers et al (2009, GSE13063) [172] 
 
GSM327154 to GSM327161 8 
Vollmers et al (2009, GSE13064) [172] 
 
GSM327162 to GSM327169 8 
Huang et al (2008, GSE13149) [173] GSM329271 to GSM329295 25 
Yates et al (2009, GSE15633) [174] GSM391335 to GSM391340 6 
Mohapatra et al (2010, GSE16207) [175] GSM406976 to GSM406993 18 
Tisserand et al (2011, GSE19675) [176] GSM491305 to GSM491308, 
GSM491317 to GSM491321 
9 
Uehara et al (2011, GSE20562) [177] GSM516651 to GSM491321 20 
Lee et al (2010, GSE21224) [178] GSM530635 to GSM530650 16 
Lee et al (2010) N.A. GSM541742 to GSM541757 16 
Yu et al (2010, GSE21861) [179] 
GSM543655, 57, 59, 61 
GSM543655, GSM543657, 
GSM543659, GSM543661 
4 
Dateki et al (2010, GSE22534) [180] GSM559519, GSM559520 2 
Dateki et al (2010, GSE22535) [180] GSM559521 to GSM559524 4 
Ding et al (2010, GSE 22879) [[181] GSM565203 to GSM565206 4 
Mongan et al (2010, GSE23780) [182] GSM586822 to GSM586831 10 
Duval et al (2010, GSE24031) [183] GSM591473 to GSM591490 18 
Edmonds et al (2011, GSE26695) [184] GSM657144 to GSM657163 20 
Pachikian et al (2011, GSE26986) [185] GSM664751 to GSM664754 4 
Zhang et al (2011, GSE27038) [186] GSM665999 to GSM666001, 
GSM666005 to GSM666007 
6 
Table 5.2A Summary of microarray expression datasets included to reconstruct the control 
liver model 
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Authors of study 
(Year, GSE number) 
Mouse strain GSM sample numbers Number of 
samples in 
each study 
Stewart et al (2010, 
GSE24637) [187] 
TALLYHO x C57BL6 F2 GSM607572 to GSM 
607587 
16 
Davis et al (2011, 
GSE 30140) [188] 
C57BL/6 x DBA/2 F2 GSM746336 to GSM 
746551 
264 
Table 5.2B Summary of microarray expression datasets included to reconstruct the diabetic 
liver model 
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Input substrate 
reaction 
Gluconeogenic 
substrate 
Max 
glucose/substrate 
flux 
EX_glyc(e) Glycerol 0.484 
EX_lac_L(e) L-Lactate 0.343 
EX_ala_L(e) Alanine 0.336 
EX_gln_L(e) L-Glutamine 0.497 
EX_pyr(e) Pyruvate 0.272 
EX_thr_L(e) L-Threonine 0.420 
EX_arg_L(e) L-Arginine 0.584 
EX_asn_L(e) L-Asparagine 0.275 
EX_asp_L(e) L-Aspartate 0.319 
EX_cys_L(e) L-Cysteine 0.316 
EX_glu_L(e) L-Glutamate 0.527 
EX_gly(e) Glycine 0.017 
EX_his_L(e) L-Histidine 0.356 
EX_ile_L(e) L-Isoleucine 0.750 
EX_met_L(e) L-Methionine 0.303 
EX_phe_L(e) L-Phenylalanine 0.616 
EX_pro_L(e) L-Proline 0.620 
EX_ser_L(e) L-Serine 0.230 
EX_trp_L(e) L-Tryptophan 0.600 
EX_tyr_L(e) L-Tyrosine 0.685 
EX_val_L(e) L-Valine 0.500 
Table 5.3 Gluconeogenic simulations. In all simulations, the optimized reaction is EX_glu-
D(e). 
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Optimized reaction Metabolite Max ketone 
body/fatty acid 
flux 
EX_acac(e) Acetoacetate 1.50 
EX_bhb(e) Β-hydroxybutyrate 1.48 
Table 5.4A Ketogenic simulations 
Optimized reaction Tested sugar mol ATP/mol sugar 
ATPM Fructose 22.8 
ATPM Galactose 22.8 
ATPM Mannose 22.8 
Table 5.4B Alternative sugar simulations 
Simulation Optimized reaction Reaction in the 
model 
Metabolite uptake 
rate 
Ammonia 
detoxification 
Ammonia uptake EX_nh4(e) 
 
Maximized 
Ethanol degradation Ethanol uptake EX_etoh(e) Maximized 
Amino acid 
degradation 
Amino acid uptake EX_asn_L(e)* Maximized 
Table 5.4C Ammonia, ethanol and amino acid degradations 
* In the table L-Asparagine was used as a model amino acid to demonstrate the simulation process, all 20 
amino acids were tested in both networks.  
Optimized reaction Reaction equation Tested metabolite Mol metabolite/mol 
glucose 
DM_glycogen(c) glycogen[c]  Glycogen, cytosol 0.077 
DM_chsterol(c) chsterol[c]   Cholesterol, cytosol 0.091 
Table 5.4D Glycogen and cholesterol production simulations 
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Simulation  Reaction added Reaction equation Entrez 
Genes ID 
Ketogenesis EX_stcoa(e) stcoa[e] <=>  N.A 
Ketogenesis STCOAt stcoa[e] <=> stcoa[c] N.A 
Alternative sugar 
metabolism 
FRUt4 na1[e] + fru[e] <=> na1[c] + fru[c] 230612.1 
Alternative sugar 
metabolism 
MAN6PI man6p[c] <=> f6p[c] 110119.1 
Gluconeogenesis CSNAT2c coa[c] + pcrn[c] <=> ppcoa[c] + crn[c] 12908.1 
Glycogen production Tyr_ggnt Tyr-ggn[e]  -> Tyr-ggn[c] N.A 
Table 5.5 Reactions added to the liver models after automatic pruning 
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Cell components Component g/100g Wet weight g/g Dry weight g/g 
Protein 17.3 [189] 0.172 0.519676 
Lipids 7.95 [190] 0.079 0.23881 
Glycogen 4 [191] 0.040 0.120156 
Water 70.5 [192] 0.702 N.A. 
DNA 0.15 [193] 0.001 0.004506 
RNA 0.53 [194] 0.005 0.015921 
Total 100.43 1.00 1.00 
Table 5.6 Composition of the mouse liver cell 
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Amino acid nmol/g tissue Amino acid nmol/g tissue 
alanine 3.239 leucine 0.221 
arginine 0.032 lysine 0.476 
asparagine 0.143 methionine 0.062 
aspartate 7.47 phenylalanine 0.087 
cysteine 0.013 proline 0.194 
glutamate 1.772 serine 0.957 
glutamine 5.369 threonine 0.446 
glycine 2.249 tryptophane 0.01 
histidine 0.697 tyrosine 0.131 
isoleucine 0.142 valine 0.215 
Table 5.7A Amino acid of mouse liver cell. All values correspond to the rat data [195] 
Lipids %(g/g lipids) 
Sphingomyelin 0.015 
Cholesterol 0.052 
Cholesterol esters 0.028 
Monophosphoinosito  0.048 
Phosphatidylethanolamine 0.093 
Phosphatidylcholine and lisolecithin  0.246 
Cardiolipin  0.017 
Triacylglycerol  0.386 
Total 0.885 
Table 5.7B Lipid composition of the mouse liver tissue [196] 
DNA mol/mol DNA RNA mol/mol RNA 
dAMP 0.3 AMP 0.18 
dCMP 0.2 CMP 0.3 
dGMP 0.2 GMP 0.34 
dTMP 0.3 UMP 0.18 
Table 5.7C Nucleotide composition of the mouse liver cell [197] 
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS 
 
The last decade has witnessed an explosion in the amount of omics data generated by high-
throughput technologies. The large amount of digital information enables a systems level 
understanding of the dependencies and correlations among molecular components. In my Ph.D. 
research work, I focused on utilizing a systems approach to analyze and characterize various 
diseases by exploring available transcriptomics, proteomics and metabolomics data.   
In addition to analyzing a wide range of data types, I also studied a variety of diseases: human 
astrocytoma, mouse glioblastoma and mouse diabetes. In collecting and integrating proteomics 
and transcriptomics data from multiple lab sources, I utilized a uniform processing platform to 
increase sample-to-sample correlation and decrease heterogeneity across the data collected in 
different studies. To further mitigate biological noise and maximize disease effect, I also 
analyzed gene or protein expression levels in the context of biological network behaviors, which 
takes interactions among related gene or proteins into account and helps to link changes in gene 
expression to phenotype.  
More specifically, I investigated and explored cancer aggressiveness and heterogeneity in the 
context of human astrocytoma, using transcriptomic data. Leveraging a large cohort of publicly 
available gene expression data sets, I have conducted the first meta-analysis that examines 
together the transcriptomes of three astrocytoma grades along with corresponding normal 
samples. I combined individual gene- and network-based approaches to identify meaningful 
patterns of expression within and between different grades. I quantified network dysregulation in 
each tumor grade and concluded that there is increasing inter-patient transcriptomic 
heterogeneity in more aggressive astrocytomas. Using a gene-based methodology, I also 
identified individual genes that exhibit monotonically increasing or decreasing expression with 
increased grade.  
Having examined the heterogeneity in high grade astrocytoma, I moved on to develop pipelines 
to identify biomarkers indicative of clinical outcome. I developed an automated framework to 
screen all candidate networks in the pre-defined network database and discovered the 
erythropoietin network that is predictive of survival in HGA patients. This signature is known to 
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mediate neuroprotection through NF-κB signaling (EPONFκB). If the EPONFκB network is 
combined with previously reported signatures, the predictive power outperformed histology-
based grading or those separated solely based on proneural/non-proneural status as predictors of 
survival. This pipeline is scalable and is capable of screening through a large number of 
networks rapidly and efficiently. For the EPONFκB network to move into clinical practice and 
adopted by medical doctors in regular diagnosis and prognosis, future experimental validation 
involving many more patients is required.  
The mouse is usually the organism of choice to study human disease, and in the proteomics 
section of my dissertation, I analyzed large-scale proteomics data collected at different stages of 
mouse glioblastoma. Protein profiling was done on three genetically engineered mouse strains 
and over 2000 proteins were tracked at three tumor development stages: early, middle, and late. 
Individual proteins and networks that were most perturbed when GBM developed as a result of 
one or more major signaling pathways that exhibit frequent aberrant behavior in GBM become 
dysfunctional were identified. Ongoing experimental work is in progress to validate the selective 
protein targets of the genes.   
Last, I developed the first genome-wide metabolic models for the C57BL/6J mouse liver,  under 
normal and diabetic conditions, using mouse whole cell model as a starting point. I started with 
improving and refining the state-of-art generic metabolic model for mice, and then compared and 
chose the most suitable algorithm for reaction selection, eventually I successfully created 
relevant working liver models that possess the basic cell functions as well as liver-specific 
functions such as gluconeogenesis and amino acid degradation. Future work could follow the 
liver model reconstruction pipeline to create similar models for other tissues. For example, we 
could create adipose and muscle metabolic models for diabetic mice, and eventually add a 
connection compartment (i.e., the blood compartment) to form a multi-tissue model by 
integrating individual tissue models [131]. 
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